Consolidated Financial Statements as of and for the Years Ended December 31, 2019 and 2018, Schedule of Expenditures of Federal Awards for the Year Ended December 31, 2019, and Independent Auditors Reports



Contents

Independent Auditor's Report	1 - 3
Consolidated Financial Statements	
Consolidated Balance Sheets	4 - 5
Consolidated Statements of Operations	6
Consolidated Statements of Changes in Net Assets	7
Consolidated Statements of Cash Flows	8 - 9
Notes to Consolidated Financial Statements	10 - 60
Supplementary Information	
Consolidating Balance Sheets	62 - 65
Consolidating Statements of Operations	66 - 67
Consolidating Statements of Changes in Net Assets	68 - 69

Independent Auditor's Report on Internal Control over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with <i>Government Auditing Standards</i>	70 - 71
Independent Auditor's Report on Compliance for Each Major Federal Program; Report on Internal Control Over Compliance Required by the Uniform Guidance	72 - 73
Schedule of Expenditures of Federal Awards	74 - 75
Notes to Schedule of Expenditures of Federal Awards	76
Schedule of Findings and Questioned Costs	77 - 78
Summary Schedule of Prior Year Findings	79



LaPorte, APAC 111 Veterans Blvd. | Suite 600 Metairie, LA 70005 504.835.5522 | Fax 504.835.5535 LaPorte.com

Independent Auditor's Report

To the Governing Board of Trustees Louisiana Children's Medical Center

Report on the Consolidated Financial Statements

We have audited the accompanying consolidated financial statements of Louisiana Children's Medical Center (the System) which comprise the consolidated balance sheets as of December 31, 2019 and 2018, and the related consolidated statements of operations, changes in net assets, and cash flows for the years then ended and the related notes to the consolidated financial statements.

Management's Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the System's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

LOUISIANA • TEXAS

An Independently Owned Member, RSM US Alliance RSM US Alliance member firms are separate and independent businesses and legal entities that are responsible for their own acts and omissions, and each is separate and independent from RSM US LLP. RSM US LLP is the U.S. member firm of RSM International, a global network of independent audit, tax, and consulting firms. Members of RSM US Alliance have access to RSM International resources through RSM US LLP but are not member firms of RSM International.

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of the System as of December 31, 2019 and 2018, and the results of its operations, changes in net assets and cash flows for the years then ended, in accordance with accounting principles generally accepted in the United States of America.

Emphasis of Matter

As discussed in Note 2 to the consolidated financial statements, the System changed its method of revenue recognition and financial statement presentation as a result of ASU 2014-09, *Revenue from Contracts with Customers (Topic 606)* and ASU 2016-02, *Leases (Topic 842)*. Our opinion is not modified with respect to this matter.

Other Matters

Other Information

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedule of expenditures of federal awards, as required by Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards,* is presented for purposes of additional analysis and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated, in all material respects, in relation to the consolidated financial statements as a whole.

The supplemental consolidating balance sheets, statements of operations, and statements of changes in net assets as of and for the years ended December 31, 2019 and 2018 are presented for the purposes of additional analysis and are not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated, in all material respects, in relation to the consolidated financial statements as a whole.

Other Reporting Required by *Government Auditing Standards*

In accordance with *Government Auditing Standards*, we have also issued our report dated May 13, 2020, on our consideration of the System's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the System's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the System's internal control over financial reporting and compliance.

A Professional Accounting Corporation

Metairie, LA May 13, 2020

LOUISIANA CHILDREN'S MEDICAL CENTER Consolidated Balance Sheets December 31, 2019 and 2018 (in Thousands)

	2019		2018	
Assets				
Current Assets				
Cash and Cash Equivalents	\$	122,753	\$ 104,836	
Assets Limited as to Use		977	967	
Patient Accounts Receivable, Net of Allowance for				
Doubtful Accounts of \$0 and \$305,678, in				
2019 and 2018, Respectively		193,443	210,095	
Pledges Receivable, Net of Discount		714	1,083	
Other Receivables		54,180	32,831	
Supplemental Payments Receivable		129,121	79,440	
Inventories		28,226	29,359	
Estimated Third-Party Payor Settlements		8,391	-	
Prepaid Expenses		59,419	55,988	
Total Current Assets		597,224	514,599	
Assets Limited as to Use				
Investments Designated for Capital Projects				
and Specific Programs		1,016,507	914,781	
Cash Restricted by Bond Indenture, Debt Service Reserve		3,317	56,989	
Donor-Restricted Long-Term Investments		12,346	10,894	
Restricted Other		136	124	
Less: Amount Required for Current Obligations		(977)	(967)	
Assets Limited as to Use, Net		1,031,329	981,821	
Pledges Receivable, Net of Discount		2,135	2,938	
Investments in Joint Ventures		57,186	55,265	
Long-term Portion of Prepaid Leases		402,400	416,894	
Property, Plant, and Equipment, Net		647,654	523,903	
Other Assets		87,667	46,501	
Total Assets	\$	2,825,595	\$ 2,541,921	

LOUISIANA CHILDREN'S MEDICAL CENTER Consolidated Balance Sheets December 31, 2019 and 2018 (in Thousands)

	2019			2018	
Liabilities and Net Assets					
Current Liabilities					
Trade Accounts Payable	\$	189,443	\$	157,288	
Accrued Salaries and Benefits		52,034		45,891	
Current Maturities of Bonds Payable, Net of					
Deferred Financing Costs		3,350		2,840	
Current Portion of Estimated Employee Health and					
Workers' Compensation Claims		7,102		9,454	
Current Portion of Estimated Professional Liabilities Claims		3,528		3,230	
Estimated Third-Party Payor Settlements		76,986		80,952	
Deferred Revenue		-		53	
Line of Credit		100,000		100,000	
Other Current Liabilities		20,669		16,452	
Total Current Liabilities		453,112		416,160	
Bonds Payable, Net of Current Portion		372,396		376,482	
Note Payable		252,488		252,368	
Estimated Employee Health and Workers'				- ,	
Compensation Claims, Net of Current Portion		6,781		5,291	
Estimated Professional Liabilities Claims, Net of				-,	
Current Portion		20,014		18,457	
Employee Benefits		9,554		6,681	
Pension Liability		10,723		9,417	
Other Long-Term Liabilities		45,420		1,028	
Total Liabilities		1,170,488		1,085,884	
Noncontrolling Interest		640		577	
Net Assets					
Without Donor Restrictions		1,642,452		1,444,231	
With Donor Restrictions					
Purpose Restrictions		6,023		5,324	
Perpetual in Nature		5,992		5,905	
Total Net Assets		1,654,467		1,455,460	
Total Liabilities and Net Assets	\$	2,825,595	\$	2,541,921	

LOUISIANA CHILDREN'S MEDICAL CENTER Consolidated Statements of Operations

For the Years Ended December 31, 2019 and 2018 (in Thousands)

	2019	2018
Revenues, Gains, and Other Support Without		
Donor Restrictions		
Net Patient Service Revenues	\$ 1,620,449	\$ 1,549,356
Provision for Doubtful Accounts	-	59,753
Net Patient Service Revenues Less Provision for		
Doubtful Accounts	1,620,449	1,489,603
Other Operating Revenues	140,841	118,801
Net Assets Released from Restrictions	 -	9,380
Total Operating Revenues	1,761,290	1,617,784
Operating Expenses		
Employee Compensation and Benefits	679,643	642,353
Purchased Services	214,316	217,925
Professional Fees	256,925	208,522
Supplies and Other Expenses	453,667	438,093
Depreciation and Amortization	74,991	65,915
Interest Expense, Net	 20,875	19,710
Total Operating Expenses	 1,700,417	1,592,518
Income from Operations	60,873	25,266
Investment Income (Loss)	158,206	(46,409)
Other Nonoperating Income	142	5,203
Community Support, Net	 (22,771)	(12,549)
Excess of Revenues over Expenses	\$ 196,450	\$ (28,489)

LOUISIANA CHILDREN'S MEDICAL CENTER Consolidated Statements of Changes in Net Assets For the Years Ended December 31, 2019 and 2018 (in Thousands)

	2019		2018
Changes in Net Assets Without Donor Restrictions			
Excess (Deficit) of Revenues over Expenses	\$ 196,450	\$	(28,489)
Excess of Revenues over Expenses Attributable			
to Noncontrolling Interests	(90)		(117)
Adjustment to Additional Minimum			
Pension Liability	(939)		(670)
Contribution of Right of Use Designated Equipment	2,800		1,366
Ownership Revisions	 -		(23)
Increase (Decrease) in Net Assets Without Donor Restrictions	198,221		(27,933)
Changes in Net Assets With Donor Restrictions			
Contributions and Grants	1,578		3,566
Investment Income (Loss)	1,521		(417)
Net Assets Released from Restriction	 (2,313)		(9,380)
Increase (Decrease) in Net Assets With Donor Restrictions	 786		(6,231)
Increase (Decrease) in Net Assets	199,007		(34,164)
Net Assets, Beginning of Year	 1,455,460		1,489,624
Net Assets, End of Year	\$ 1,654,467	\$	1,455,460

LOUISIANA CHILDREN'S MEDICAL CENTER Consolidated Statements of Cash Flows For the Years Ended December 31, 2019 and 2018 (in Thousands)

	2019	 2018
Cash Flows from Operating Activities		
Increase (Decrease) in Net Assets	\$ 199,007	\$ (34,164)
Adjustments to Reconcile Increase (Decrease) in Net Assets		
to Net Cash Provided by Operating Activities		
Adjustment to Pension Liability	939	670
Noncontrolling Interest in Income of Consolidated		
Subsidiaries	90	117
Depreciation and Amortization	74,991	65,915
Depreciation Related to Community Support	810	714
Loss on Extinguishment of Debt	-	1,205
Amortization of Debt Issuance Costs Included in Interest Expense	(670)	(112)
Equity in Earnings of Investments in Joint Ventures	(7,409)	(7,538)
Net Realized and Unrealized Investment (Income) Loss	(159,729)	46,548
Provision for Doubtful Accounts	-	59,753
Non-Cash Reduction of Contingent Performance Obligation	-	(6,667)
(Increase) Decrease in:		
Patient Accounts Receivable	16,652	(106,646)
Other Receivables and Supplemental Payments Receivable	(69,858)	6,330
Inventories	1,133	(1,505)
Prepaid Expenses	(3,431)	25,712
Other Assets	(41,178)	(34,691)
Increase (Decrease) in:		
Trade Accounts Payable	19,792	20,954
Accrued Salaries and Benefits	6,143	1,718
Third-Party Payor Settlements	(12,357)	11,317
Deferred Revenue	(53)	21
Other Liabilities	 52,842	4,851
Net Cash Provided by Operating Activities	 77,714	54,502
Cash Flows from Investing Activities		
Investment in Joint Venture	(2,225)	(700)
Distributions of Earnings of Investments in Joint Ventures	7,713	8,286
Capital Expenditures	(172,697)	(167,608)
Purchases of Investments	(5,299)	(248,200)
Proceeds from Sales of Investments	 115,522	348,937
Net Cash Used in Investing Activities	(56,986)	(59,285)

LOUISIANA CHILDREN'S MEDICAL CENTER Consolidated Statements of Cash Flows (Continued) For the Years Ended December 31, 2019 and 2018 (in Thousands)

	2019	2018
Cash Flows from Financing Activities		
Proceeds from Issuance of Bonds	-	202,485
Proceeds from Line of Credit, Net	-	25,000
Repayments of Bonds Payable	-	(202,675)
Return of Capital from Investment in Subsidiary	-	5,047
Payments of Debt Issuance Costs - Series 2015A	(2,786)	(2,392)
Distributions Paid to Noncontrolling Interest	 (27)	(161)
Net Cash (Used in) Provided by Financing Activities	 (2,813)	27,304
Net Increase in Cash and Cash Equivalents	17,915	22,521
Cash and Cash Equivalents, Beginning of Year	 104,836	82,315
Cash and Cash Equivalents, End of Year	\$ 122,751	\$ 104,836
Supplemental Disclosures of Cash Flow Information		
Cash Paid for Interest	\$ 35,536	\$ 31,171
Non-Cash Disclosures:		
Property, Plant, and Equipment Purchases in Accounts Payable	\$ 19,893	\$ 7,531

Notes to Consolidated Financial Statements

Note 1. Organization

Louisiana Children's Medical Center (LCMC) is a Louisiana non-stock, not-for-profit corporation that was incorporated in 2009, with its founding member being Children's Hospital (Children's). Through a Health Care System Agreement between LCMC, Children's and its subsidiaries, Touro Infirmary and its subsidiaries (Touro), and Cooperative Endeavor Agreements (CEAs) with University Medical Center Management Corporation (UMCMC) and West Jefferson Holdings, LLC and its subsidiary (West Jefferson), these parties have determined that together they can provide a multi-hospital, not-for-profit community-based, system that will provide a continuum of care to the families of the Gulf South region. LCMC, Children's, Touro, UMCMC, West Jefferson, LCMC Health Anesthesia Corporation, and LCMC Health Clinical Services, LLC are hereinafter collectively referred to as the System. LCMC functions as the System and its affiliates. All corporate powers of the System are vested in the Board of Trustees of LCMC.

Children's is Louisiana's only full-service hospital operated exclusively for children. Children's, together with its affiliate, the Children's Hospital Medical Practice Corporation (CHMPC), are tax-exempt under Section 501(c)(3) of the Internal Revenue Code (the Code). Located in New Orleans, Louisiana, Children's includes a 224-bed medical center providing care for infants, children, and adolescents from birth to 21 years of age. It provides inpatient services in all pediatric, medical, surgical, and psychiatric subspecialties with a staff of more than 440 physicians. Outpatient services are provided in 58 subspecialties.

Children's provides a large array of community benefit and wellness programs including research activities, and special programs for the handicapped and medically underserved. CHMPC was incorporated to manage pediatric physician practices in a high-quality, cost-effective manner. Kids First, a division of CHMPC, provides pediatric care in medically underserved geographical areas.

Touro Infirmary, and its 280 staffed beds, is New Orleans' only community-based, not-forprofit, faith-based hospital. It is exempt from taxation under the Code. Touro Infirmary is the sole member of Woldenberg Village, Inc. (Woldenberg), and Touro Infirmary Foundation, both of which are non-stock, not-for-profit, and tax-exempt corporations. Touro Infirmary is the sole stockholder of Crescent City Physicians, Inc. (CCPI), a for-profit corporation; and holds a majority interest, together with Woldenberg, in TIJV, LLC, a forprofit limited liability company.

Notes to Consolidated Financial Statements

Note 1. Organization (Continued)

UMCMC operates as a corporation affiliated with Louisiana State University (LSU) as defined in LA R.S. 17:3390, with a principal purpose of supporting the programs, facilities and research and educational opportunities offered by LSU, and supporting research and educational opportunities, including, without limitation, medical training programs offered by the Administrators of the Tulane Educational Fund (Tulane), including, without limitation, the following: (i) operating University Medical Center in New Orleans (UMC); (ii) operating in a manner consistent with the best practices of private, nonprofit institutions; (iii) being a provider of financial assistance for the uninsured and playing a pivotal role as a statewide referral center for patients in need of tertiary care; (iv) providing medical and allied health training; and, (v) being recognized nationally as a leader in research, training, and excellence in transparent clinical and financial outcomes.

UMCMC, with its vision of being an integrated, world class academic medical center acknowledges that LCMC has the resources and expertise necessary to achieve its vision. LCMC is the sole corporate member of UMCMC. On May 29, 2013, UMCMC and LCMC, entered into an Amended and Restated CEA (UMC CEA) with the Board of Supervisors of LSU, the Louisiana Division of Administration, the State of Louisiana (the State), through its Division of Administration. The objective of the UMC CEA is to maintain the viability of operations and patient care services and programs at UMC, thereby stabilizing and preserving academic medicine in Louisiana.

The UMC CEA was entered into for the public purpose of creating an academic medical center in which the parties continuously work in collaboration and are committed and aligned in their actions and activities, in a manner consistent with a sustainable business model and adequate funding levels, to serve the State and its citizens: (i) as a premier site for graduate medical education, capable of competing in the health care marketplace, comparable among its peers, with the goal of attracting the best faculty, residents and students, to enrich the State's health care workforce and their training experience; (ii) in fulfilling the State's historical mission of assuring access to safety net services to all citizens of the State, including its medically indigent, high risk Medicaid and State inmate populations, and (iii) by focusing on and supporting the core services and key service lines, as defined and agreed by the parties, necessary to assure high quality programs and access to safety net services.

The UMC CEA also provides that UMCMC will enter into academic affiliation agreements with LSU, Tulane, Xavier University, Dillard University, University of New Orleans, Delgado Community College, and other academic institutions to strengthen and enhance opportunities to achieve the State's medical education, clinical care and research goals as part of a collaborative academic medical center (the AMC). UMCMC and LCMC commit to supporting the academic, clinical and research missions of the AMC.

Notes to Consolidated Financial Statements

Note 1. Organization (Continued)

The UMC CEA further provides that LSU will lease UMC and certain furniture, fixtures, and equipment used in connection with operating UMC to UMCMC, that LSU and the State will grant to UMCMC a right of use of the land upon which UMC is constructed and operated and certain land improvements surrounding UMC pursuant to a Right of Use agreement, and that UMCMC and LCMC will commit to supporting the academic, clinical and research missions of the AMC, as defined within the UMC CEA.

As prescribed in the UMC CEA, LCMC may withdraw as the sole member of UMCMC, without cause, upon providing sixty days advance written notice. For additional details of this UMC CEA see Note 19.

In November 2014, West Jefferson was formed pursuant to an operating agreement with LCMC being the sole member, having exclusive authority to direct, manage, control, and make all decisions regarding the business and affairs of West Jefferson to act in conjunction with the purposes of LCMC. West Jefferson operates a 435-bed hospital located in Marrero, Louisiana providing general acute care along with clinical and other health care operations at various other locations in the New Orleans metropolitan area.

West Jefferson operates via assets leased to it by Jefferson Parish Hospital District No. 1, Parish of Jefferson, State of Louisiana, d/b/a West Jefferson Medical Center (the District) under the terms of a CEA (WJ CEA) and a Master Hospital Lease. The WJ CEA was entered into on February 26, 2015, by and among LCMC, West Jefferson, and the District in order to maintain the viability of operations and range of patient care services and programs previously provided by the District. West Jefferson began operating the assets leased to it by the District effective October 1, 2015. The terms and conditions of the WJ CEA and the Master Hospital Lease are further described in Note 19.

On September 18, 2016, West Jefferson became the sole member of New Orleans Physician Services, Inc. (NOPS). NOPS is organized and operated exclusively for charitable, educational, and scientific purposes, and for the delivery of healthcare services, including free healthcare services to indigent persons, in Jefferson Parish.

Prior to February 6, 2017, Children's was the sole member of its affiliate, Children's Hospital Anesthesia Corporation (CHAC), a tax-exempt corporation. CHAC was incorporated to provide high quality, comprehensive anesthesia services. Effective February 6, 2017, LCMC and Children's executed a member Substitution agreement whereby LCMC became the sole member of Children's Hospital Anesthesia Corporation (CHAC). This was a common control transaction and had no impact on the assets and liabilities of CHAC. The purpose of the member substitution was to allow CHAC to become the primary provider of anesthesia services to the hospitals within the System. After the member substitution, CHAC's name was changed to the LCMC Health Anesthesia Corporation (LHAC).

Notes to Consolidated Financial Statements

Note 1. Organization (Continued)

On November 20, 2017, LCMC Health Clinical Services, LLC, (LHCS) was formed by LCMC as its sole member. LHCS had no activities from its inception through December 31, 2017. LHCS activities began January 1, 2018. The revenues generated at LHCS from unconsolidated affiliates do not support the costs of its operations, and the System records the activities of LHCS in community support, net in the consolidated statements of operations.

On June 18, 2019, Audubon Retirement Village (ARV) was formed by LCMC as its sole member.

Effective June 28, 2019, LSU and ARV executed a Cooperative Endeavor Agreement (CEA) whereby ARV will operate the John J. Hainkel Jr. Home and Rehabilitation Center (Nursing Home) with the public purpose of establishing a Geriatric Training Nursing Facility (GTNF Program) where much needed graduate medical education will be conducted to train physicians and allied health professionals in the provision of care to the elderly and needy residents of Louisiana.

Recognizing the importance of the GTNF Program, ARV and LSU will enter into academic affiliation and/or professional service agreements, as necessary, to collaborate in establishing the GTNF Program.

ARV began operations with the execution of a lease agreement of the Nursing Home on June 28, 2019, that is more fully described in Note 19.

Note 2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying consolidated financial statements of the System include the activities of LCMC, Children's, Touro, UMCMC, West Jefferson, LHAC, LHCS, and ARV. All significant intercompany transactions have been eliminated in consolidation.

The System also provides management services to New Orleans East Hospital (NOEH) as further described in Note 19. However, the activities of NOEH are not consolidated with the System because NOEH is controlled by another party.

Financial statement preparation follows accounting principles generally accepted in the United States of America (GAAP), which requires the System to report information regarding its financial position and activities according to two classes of net assets: net assets without donor restrictions and net assets with donor restrictions.

Notes to Consolidated Financial Statements

Note 2. Summary of Significant Accounting Policies (Continued)

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period.

The System considers critical accounting policies to be those that require more significant judgments and estimates in the preparation of its consolidated financial statements, including the following: recognition of net patient revenue, which includes explicit and implicit pricing concessions, such as contractual allowances discounts, collectability assessment of outstanding accounts receivables, and charity care; losses and expenses related to the self-insured workers' compensation, professional liabilities, and employee health claims; and risks and assumptions for measurement of pension and other postretirement liabilities. Management bases its estimates on historical experience and various other assumptions that it believes are reasonable under the particular facts and circumstances. Actual results could differ from those estimates.

Cash and Cash Equivalents

Cash and cash equivalents include certain investments in highly liquid debt instruments with a remaining maturity of three months or less when purchased, excluding assets whose use is limited or restricted.

Inventories

Inventories are stated at the lower of first-in, first-out cost, or at its market value at the date of the consolidated balance sheets.

Assets Limited as to Use

Assets whose use is limited primarily include assets held by trustees indenture agreements, investments with donor restrictions, and designated assets set aside by the Board of Trustees (Board) for future capital improvements and commitments, over which the Board retains control and may, at its discretion, subsequently use for other purposes.

These investments are recorded at fair value with changes in fair value recorded in the consolidated statements of operations. Fair value estimates are made at a specific point in time, based on market conditions and information about the investments. These estimates are subjective in nature and involve uncertainties and matters of judgment. Changes in assumptions could affect the estimates.

The investments in marketable alternative investments are valued by management at their equity in the net assets of the investment, which approximates fair value, utilizing the net asset valuation provided by the underlying investment companies, unless management determines some other valuation is more appropriate. Such fair value estimates do not reflect early redemption penalties or redemption restrictions as the System does not intend to sell such investments before the expiration of the early redemption periods.

Notes to Consolidated Financial Statements

Note 2. Summary of Significant Accounting Policies (Continued)

Leases

Accounting Standards Update (ASU) 2016-02 was issued to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The adoption of ASU 2016-02 was accomplished using a modified retrospective method of application, with accounting policies related to leases revised accordingly, effective January 1, 2019, as discussed below.

The System determines if an arrangement is a lease at inception of the contract. Rightof-use assets represent the right to use the underlying assets for the lease term, and lease liabilities represent the obligation to make lease payments arising from the leases. Rightof-use assets and lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The System uses its estimated incremental borrowing rate, which is derived from information available at the lease commencement date, in determining the present value of lease payments.

The System's operating leases are primarily for real estate, including off-campus outpatient facilities, medical office buildings, and corporate and other administrative offices. The System's real estate lease agreements typically have initial terms of 4 to 30 years. In line with this ASU, the System does not record right-of-use assets and lease liabilities on leases with an initial term of 12 months, or less, in the consolidated balance sheets.

The System's real estate leases may include one or more options to renew, with renewals extending the lease term for multiple years. The exercise of lease renewal options is at the System's sole discretion. In general, the System does not consider it reasonably likely that renewal options will be exercised; therefore, renewal options are generally not recognized as part of right-of-use assets and lease liabilities.

Certain of the System's lease agreements for real estate include rental payments adjusted periodically for inflation. These variable lease payments are recognized in supplies and other expenses, but are not included in the right-of-use asset or liability balances. The System's lease agreements do not contain any material residual value guarantees, restrictions, or covenants.

The System elected the practical expedient method that allows lessees to choose to not separate lease and non-lease components by class of underlying asset and is applying this expedient to all relevant asset classes.

Notes to Consolidated Financial Statements

Note 2. Summary of Significant Accounting Policies (Continued)

Property, Plant, and Equipment

Property, plant, and equipment are stated at cost, except for assets donated to the System. Donated assets are recorded at their estimated fair value at the date of donation.

Depreciation and amortization, which includes amortization of assets under capital lease and the amortization of prepaid operating leases related to the UMC CEA and WJ CEA, are computed on the straight-line basis over term of the operating leases and the estimated useful lives, or shorter of useful life or lease term for capital leases, as follows:

Land Improvements	10 - 20 Years
Buildings	15 - 40 Years
Leasehold Improvements	3 - 5 Years
Fixed Equipment	10 - 20 Years
Major Moveable Equipment	3 -10 Years

Impairment of Long-Lived Assets

The System reviews its long-lived assets, including property and equipment and other intangibles, for impairment and determines whether an event or change in facts and circumstances indicates that their carrying amount may not be recoverable.

The System determines recoverability of the assets by comparing their carrying amount to the net future undiscounted cash flows that the asset is expected to generate or estimated fair values in the case of nonrevenue generating assets. When the carrying value of an asset exceeds the estimated recoverability, an asset impairment charge is recognized.

Prepaid Expenses and Other Assets

In accordance with the UMC CEA mentioned in Notes 1 and 19, advance rent payments, in the amount of \$253,000,000, were made on the UMC lease. Of this total, \$110,000,000 represents a prepayment of a portion of the UMC facility, with the exception of its ambulatory care center and its garage, while \$143,000,000 represents all future rent payments for the ambulatory care building and garage. Due to the notes payable, described in Note 11, being directly related to funding the advance rent payments, UMCMC deferred the recognition of interest payments made through August 1, 2015, which is when operations transitioned to the new facility. As described in Note 19, these advance payments and the deferred interest were applied to the annual rental requirements of UMC.

As of December 31, 2019 and 2018, the amounts classified as current were approximately \$10,050,000 and are included within prepaid expenses on the consolidated balance sheets. As of December 31, 2019 and 2018, the amounts classified as non-current were approximately \$225,733,000 and \$235,783,000, respectively.

Notes to Consolidated Financial Statements

Note 2. Summary of Significant Accounting Policies (Continued)

Prepaid Expenses and Other Assets (Continued)

In accordance with the WJ CEA and the Master Hospital Lease, related to West Jefferson, mentioned in Notes 1 and 19, an advance rent payment in the amount of \$200,000,000 was made on September 30, 2015. This advance payment is being applied to the annual rent requirements of West Jefferson over the lease terms.

As of December 31, 2019 and 2018, the amounts classified as current were approximately \$4,444,000 and are included within prepaid expenses on the consolidated balance sheets. As of December 31, 2019 and 2018, the amounts classified as non-current were approximately \$176,667,000 and \$181,111,000.

Deferred Financing Costs and Original Issue Premium

Deferred financing costs, original issue premiums, and original issue discounts are netted with the related debt and are amortized over the period the obligation is outstanding using a method that approximates the interest method.

Deferred financing costs are presented net of accumulated amortization. Net deferred financing costs total approximately \$3,457,000 and \$3,742,000 at December 31, 2019 and 2018, respectively.

Original issue premiums are presented net of accumulated amortization. Net original issue premiums total approximately \$19,176,000 and \$20,077,000 at December 31, 2019 and 2018, respectively.

Estimated Workers' Compensation, Professional Liability, and Employee Health Claims

The System records the provisions for estimated medical, professional, and general liability, and workers' compensation claims based upon actual claims incurred, combined with an estimate of claims incurred but not reported. Claims expense is reduced by amounts recoverable through stop-loss insurance purchased by the System. Estimates recorded for these self-insured liabilities incorporate the System's past experience, as well as other considerations including the nature of claims, industry data, relevant trends, and/or the use of actuarial information.

The System follows ASU 2010-24, *Health Care Entities (Topic 954): Presentation of Insurance Claims and Related Insurance Recoveries*, which clarifies that a health care entity should not net insurance recoveries against a related claim liability.

Pension and Other Postretirement Plans

The System recognizes the overfunded or underfunded status of its pension and other postretirement plans as an asset or liability in its consolidated balance sheets. Changes in the funded status of the pension and other postretirement plans are reported as a change in unrestricted net assets presented below the excess of revenues over expenses financial statement line item in the consolidated statement of changes in net assets in the year in which the changes occur.

Notes to Consolidated Financial Statements

Note 2. Summary of Significant Accounting Policies (Continued)

Deferred Revenue

When the System receives payments for providing services in advance of it providing those services, recognition of revenue is deferred until the period in which the services are provided, and all obligations of the System are relieved.

Fair Value of Financial Instruments

The System accounts for certain assets and liabilities at fair value or on a basis that approximates fair value. A fair value hierarchy for valuation inputs prioritizes the inputs into three levels based on the extent to which inputs used in measuring fair value are observable in the market. Each fair value measurement is reported in one of the three levels and is determined by the lowest level input that is significant to the fair value measurement in its entirety. These levels are:

- Level 1 Quoted prices are available in active markets for identical assets or liabilities as of the measurement date. Financial assets in this category primarily include listed equities.
- Level 2 Pricing inputs are based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and for which all significant inputs are observable, either directly or indirectly, as of the measurement date. Financial assets and liabilities in this category generally include asset-backed securities, corporate bonds and loans, municipal bonds, and interest rate swaps.
- Level 3 Pricing inputs are generally unobservable and include situations where there is little, if any, market activity for the investment. The inputs into the determination of fair value require management's judgment or estimation of assumptions that market participants would use in pricing the assets or liabilities. Financial assets in this category generally include alternative investments.

Derivatives and Financial Instruments

The System uses interest rate swap and basis swap agreements to manage interest costs and the risk associated with changing interest rates. The fair value of these instruments is recorded in other receivables or other current liabilities on an instrument by instrument basis depending on the current value in the consolidated balance sheets. While the System's primary objective for the use of these instruments is to manage its cash flow requirements, unrealized gains and losses in the fair value of such instruments are reflected in investment income or loss in the consolidated statements of operations in accordance with the *Accounting for Derivative Instruments and Hedging Activities* Topic of the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC).

Notes to Consolidated Financial Statements

Note 2. Summary of Significant Accounting Policies (Continued)

Patient Service Revenue

Patient service revenue is reported at the amount that reflects the consideration to which the System expects to be entitled for providing patient care. These amounts are due from patients and third-party payors and include variable consideration for retroactive revenue adjustments due to settlement of reviews and audits as well as supplemental payments related to current period operations. Generally, the System bills the patients and thirdparty payors after the services are performed or shortly after discharge. Revenue is recognized as performance obligations are satisfied. Performance obligations are determined based on the nature of the services provided by the System.

Revenue for performance obligations satisfied over time is recognized based on actual charges incurred, which is reduced by an amount that reflects the consideration expected to be received for the services provided based on historic collection patterns. The System believes that this method provides a reasonable depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation.

Generally, performance obligations satisfied over time relate to patients receiving inpatient acute care services. The System measures the performance obligation from admission into the hospital to the point when it is no longer required to provide services to that patient, which is generally at the time of discharge. These services are considered to be a single performance obligation. Revenue for performance obligations satisfied at a point in time is recognized when services are provided. Management believes this method provides an accurate depiction of the transfer of services over the term of performance obligations based on the inputs needed to satisfy the obligations.

The System recognizes revenue for performance obligations satisfied at a point in time, which generally relate to patents receiving outpatient services, when: (1) services are provided; and (2) the patient no longer requires additional services.

Because its performance obligations relate to contracts with a duration of less than one year, the System has elected to apply the optional exemption provided in FASB ASC 606-10-60-14(a), and therefore, is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period. As provided for under the guidance, the System does not adjust the expected net revenue from patients and third-party payors for the effects of a significant financing component due to the expectation that the period between the time the service is provided to a patient and the time that the patient or a third-party payor pays for that service will be one year or less.

Notes to Consolidated Financial Statements

Note 2. Summary of Significant Accounting Policies (Continued)

Patient Service Revenue (Continued)

The System is utilizing the portfolio approach practical expedient in ASC 606 for contracts related to patient service revenue. The System accounts for the contracts within each portfolio as a collective group, rather than individual contracts, based on the payment pattern expected in each portfolio category and the similar nature and characteristics of the patients within each portfolio. The portfolios consist of major payor classes for inpatient and outpatient revenue. Based on historical collection trends and other analyses, the System has concluded that revenue for a given portfolio would not be materially different from accounting for revenue on a contract-by-contract basis.

Gross charges differ from actual pricing and generally do not reflect what a hospital is ultimately paid and, therefore, are not displayed in the consolidated statements of operations. The System has agreements with third-party payors that generally provide for payments at amounts different from the System's established rates. For uninsured patients who do not qualify for financial assistance, the System recognizes revenue based on established rates, subject to certain discounts and implicit price concessions in accordance with its policy.

The System determines the transaction price based on standard charges for services provided, reduced by explicit price concessions provided to third-party payors, discounts provided to patients in accordance with policy, and implicit price concessions provided to patients. Explicit price concessions are based on contractual agreements, discount policies, and historical experience. Implicit price concessions represent differences between amounts billed and the estimated consideration the System expects to receive from patients, which are determined based on historical collection experience, current market conditions, and other factors. Generally, patients who are covered by third-party payors are responsible for patient responsibility balances, including deductibles and coinsurance, which vary in amount. The System estimates the transaction price for patients with deductibles and coinsurance based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by any explicit price concessions, discounts, and implicit price concessions.

Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to patient service revenue in the period of the change when new information is available. This includes provisions for third-party payor settlements and supplemental payments. Adjustments arising from a change in the transaction price were not significant in 2019 or 2018.

Notes to Consolidated Financial Statements

Note 2. Summary of Significant Accounting Policies (Continued)

Patient Service Revenue (Continued)

Settlements with third-party payors for retroactive adjustments due to review and audits are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care in the period the related services are provided using the most likely outcome method. The System records retroactive Medicare and Medicaid settlements based upon estimates of amounts that are ultimately determined through annual cost reports filed with and audited by the fiscal intermediary, correspondence from the payor and the System's historical settlement activity, including an assessment to ensure that it is probable that a significant revenue reversal in the amount of the cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known or as years are settled or are no longer subject to such reviews and audits. Adjustments arising from a change in estimated settlements increased patient service revenue by approximately \$28,212,000 and \$8,054,000 in 2019 and 2018, respectively.

Grants, Contributions, and Gifts With Donor Restrictions

From time to time, the System receives grants from individuals, private, and public entities. Revenues from grants (including contributions of capital assets) are recognized when all of the eligibility requirements, including time requirements, are met, and when there is reasonable assurance that the grants will be received. Grants may be restricted for either specific operating purposes or for capital purposes. Amounts are recorded as either operating or non-operating revenue based upon their nature.

Unconditional promises to give cash and other assets which are expected to be collected within one year are reported at fair value at the date the promise is received. Contributions that are expected to be collected in future years are recorded at fair value when the promise is made based on a discounted cash flow model. Amortization of discounts is recorded as additional contribution revenue in accordance with donor-imposed restrictions, if any, on the contributions. Conditional promises to give and indications of intentions to give are reported at fair value at the date the condition is met, or the gift is received. Gifts are reported as net assets with donor restrictions if they are received with donor stipulations that limit the use of the donated assets. When an externally-imposed restriction expires, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the consolidated statements of operations as net assets released from restrictions.

Certain net assets with donor restrictions have been restricted by donors to be maintained by the System in perpetuity.

Contributions for which the restrictions are met in the same period in which the unconditional promise to give is received are recorded as revenue without donor restrictions in the accompanying consolidated financial statements.

Notes to Consolidated Financial Statements

Note 2. Summary of Significant Accounting Policies (Continued)

Operating and Nonoperating Activities

The System's primary mission is to meet the healthcare needs in its market area through a broad range of general and specialized healthcare services. Activities directly associated with the furtherance of this purpose are considered to be operating activities. Other activities that are peripheral to the System's primary mission are considered to be nonoperating.

Excess of Revenues over Expenses

Excess of revenues over expenses includes all changes in net assets without donor restrictions except for the effect of changes in accounting principles, net assets released from restrictions used for purchase of property and equipment, change in funded status of pension obligations, change in the non-controlling interests, funds donated from unconsolidated sources for purchases of property and equipment, and the donation of property and equipment from unconsolidated sources.

Financial Assistance Program

The System provides medical care without charge or at reduced costs to residents of its community through the provision of financial assistance. The System follows ASU 2010-23, *Health Care Entities (Topic 954)*, which requires that costs be used as the measurement basis of financial assistance disclosures and that costs be identified as the direct and indirect costs of providing the financial assistance. The entities within the System each have their own unique policy for determining costs. They either: (1) assign direct costs of their financial assistance program and complement those direct costs with estimates determined from Medicare and Medicaid cost reporting methodologies, or (2) calculate a ratio of costs to usual and customary charges and apply that ratio to the usual and customary uncompensated charges associated with providing care to patients that qualify for financial assistance. The System also follows the new regulation under Section 501(r) as established by the Affordable Care Act, which requires policies for financial assistance, emergency medical care, and billing and collections.

During the years ended December 31, 2019 and 2018, estimated costs associated with providing financial assistance, throughout the System, were approximately \$48,206,000 and \$41,342,000, respectively.

Recently Adopted Accounting Pronouncements

As mentioned above, effective January 1, 2019, the System adopted the FASB ASU 2016-02, *Leases (Topic 842)* using the modified retrospective transition approach as of the period of adoption. The System's financial statements for periods prior to January 1, 2019 were not modified for the application of the new lease accounting standard. The main difference between the guidance in ASU 2016-02 and previous U.S. GAAP is the recognition of lease assets and lease liabilities on the balance sheet by lessees for those leases classified as operating leases under previous U.S. GAAP. Upon adoption of ASU 2016-02, the System recorded approximately \$53,724,000 of right-of-use assets associated with operating leases in other assets in the consolidated balance sheet, approximately \$4,424,000 of current liabilities associated with operating leases in other current liabilities in the consolidated balance sheet and approximately \$49,300,000 of other long-term liabilities associated with operating leases in other the consolidated balance sheet.

Notes to Consolidated Financial Statements

Note 2. Summary of Significant Accounting Policies (Continued)

Recently Adopted Accounting Pronouncements (Continued)

Effective January 1, 2019, the System adopted the FASB ASU 2014-09, *Revenue from Contracts with Customers (Topic 606) (ASU 2014-09)* using a modified retrospective method of application to contracts that were not complete as of the date of initial application. The core principle of the guidance in ASU 2014-09 is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The System utilized the portfolio approach practical expedient in Topic 606 to assess the impact of ASU 2014-09 on patient service revenue.

Under ASU 2014-09, the estimated uncollectable amounts due are generally considered implicit price concessions that are a direct reduction to net operating revenues, with a corresponding material reduction in the amounts presented separately as provision for doubtful accounts. For the year ended December 31, 2019, approximately \$58,554,000 of such implicit price concessions were recorded as a direct reduction of net operating revenues that would have been recorded as provision for doubtful accounts prior to the adoption of ASU 2014-09. Approximately \$346,213,000 was recorded as a direct reduction of accounts receivable, at December 31, 2019, that would have been disclosed as an allowance for doubtful accounts prior to the adoption of ASU 2014-09.

In March 2017, the FASB issued ASU 2017-07, *Compensation - Retirement Benefits* (*Topic 715*): *Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost.* ASU 2017-07 requires that an entity report the service cost component of net periodic pension and postretirement cost in the same line item or items as other compensation costs arising from services rendered by the pertinent employees during the period. The remaining components of net benefit costs are required to be presented in the consolidated statement of operations separately from the service component and outside a subtotal of excess revenues over expenses, if one is presented. The amendment further allows only the service cost component of net periodic pension and postretirement costs to be eligible for capitalization. The System used a full retrospective method to adopt ASU 2017-07 on January 1, 2019. There was no impact on the System's total excess of revenues over expenses or total net assets from adoption.

Pending Accounting Pronouncements

In August 2017, the FASB issued ASU 2017-12, *Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities.* The new guidance is intended to more closely align hedge accounting with entities' hedging strategies, simplify the application of hedge accounting, and increase the transparency of hedging programs.

The amendments in ASU 2017-12 are effective for the System beginning on January 1, 2020. For cash flow and net investment hedges existing at the date of adoption, ASU 2017-12 must be applied through a cumulative-effect adjustment. The amended presentation and disclosure guidance is required only prospectively. The System is currently evaluating the impact of the adoption of this guidance on its consolidated financial statements.

Notes to Consolidated Financial Statements

Note 2. Summary of Significant Accounting Policies (Continued)

Pending Accounting Pronouncements (Continued)

In August 2018, the FASB issued ASU 2018-13, *Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement*, which modifies the disclosure requirements for fair value measurements by removing, modifying, or adding certain disclosures. ASU 2018-13 is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The System is currently evaluating the impact of this new standard on its consolidated financial statements.

In August 2018, the FASB issued ASU 2018-14, *Compensation - Retirement Benefits - Defined Benefit Plans—General (Subtopic 715-20): Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans*, which modifies the disclosure requirements for defined benefit pension plans and other post-retirement plans. This ASU is effective for the System for fiscal years ending after December 15, 2021 and must be applied on a retrospective basis. Management anticipates that ASU 2018-14 will not have a material impact to our consolidated financial statements and related disclosures.

Income Taxes

LCMC, Children's, UMCMC, Touro, LHAC, and certain of their respective subsidiaries are not-for-profit entities under Section 501(c)(3) of the Code and are exempt from federal income taxation. West Jefferson, LHCS and ARV are considered disregarded entities for federal and state income tax purposes, with their profits and losses allocated to LCMC.

CCPI, a subsidiary of Touro, is a for-profit entity. The operations of CCPI have resulted in cumulative net operating losses for Federal income tax purposes of approximately \$59,000,000 that are available for utilization in their 2019 federal filing and forward through 2037. No tax benefits related to these operating losses have been recognized in the accompanying consolidated financial statements.

Accounting for Uncertainty in Taxes

Accounting principles generally accepted in the United States of America provide accounting and disclosure guidance about positions taken by an entity in its tax returns that might be uncertain. Penalties and interest assessed by income taxing authorities, if any, would be included in income tax expense.

The System believes that it has appropriate support for any tax positions taken, and management has determined that there are no uncertain tax positions that are material to the financial statements.

Reclassifications

Certain reclassifications have been made to the 2018 financial statement presentation to correspond to the current year's format.

Notes to Consolidated Financial Statements

Note 3. Patient Service Revenues

The System has arrangements with patients and third-party payors that provide for payments to the System at amounts different from its established rates. A summary of the payment arrangements with major payors follows:

Commercial

The System has also entered into contractual arrangements with certain commercial insurance carriers, health maintenance organizations, and preferred provider organizations. Inpatient and outpatient services rendered to patients covered by commercial insurance are reimbursed at prospectively determined rates per discharge, discounts from established charges, and prospectively determined daily rates. In general, there is a lower risk to the System on revenues recognized from commercial insurers in comparison to other third-party payors.

Medicaid

In the context of healthcare reform, effective February 1, 2012, Louisiana Medicaid introduced Bayou Health, a state-wide managed care Medicaid initiative. Medicaid recipients enroll in one of five available Bayou Health plans. The plans are all accountable to the Louisiana Department of Health (LDH) and to the State of Louisiana (State). There are differences between these plans, including their provider networks, referral policies, health management programs, services and incentives offered to participants. Medicaid recipients can select Bayou Health plan for enrollment.

The System's reimbursements from the Bayou Health plans follow the same methodology as Medicaid; that is, LDH's objective is to continue collecting all Medicaid hospital program services and costs through the annual cost report uniformly, whether the service is covered by traditional Medicaid fee for service or a Prepaid Plan.

All inpatient services, with the exception of transplants, rendered to Medicaid program beneficiaries are paid at prospectively determined per diem rates. Outpatient services rendered to Medicaid program beneficiaries are reimbursed either on a cost basis subject to certain limits or on a prospectively determined amount per procedure.

The state of Louisiana reimburses certain outpatient hospital services based on a percentage of actual cost. Since actual cost cannot be determined until after the fiscal year and the related cost report is completed, the hospitals estimate their cost-based reimbursement using prior year cost factors. The cost factors are adjusted for year-to-date changes in cost and volumes.

Transaction prices related to Medicaid revenues are more at risk of being increased or decreased in a period after the actual services were performed as described in the Third-Party Settlements section below.

Notes to Consolidated Financial Statements

Note 3. Patient Service Revenues (Continued)

Supplemental Payment Program

The System has collaborated with the State and units of local government in Louisiana to more fully fund the Medicaid program and to ensure the availability of quality healthcare services for the low income and needy residents in the community population.

The provision of this care directly to low income and needy patients will result in the alleviation of the expense of public funds the governmental entities would otherwise expend on such care, thereby allowing the governmental entities to increase support for the state Medicaid program up to Full Medicaid Pricing (FMP) and the Upper Payment Limit (UPL). The State's methodology must comply with its state plan with approval by the Centers for Medicare & Medicaid Services (CMS).

For the years ended December 31, 2019 and 2018, LCMC has recognized approximately \$192,695,000 and \$166,656,000, respectively, under the FMP/UPL program classifying it within net patient service revenue on the consolidated statement of operations. At December 31, 2019 and 2018, respectively, approximately \$80,628,000 and \$47,694,000 of these revenues were not yet collected and therefore included in Supplemental Payments Receivable in the consolidated balance sheets.

UMCMC, Touro, and West Jefferson qualify as disproportionate share providers and as teaching hospitals under the Medicaid regulations. As such, the System receives additional payments for Medicaid inpatients served. The Medicaid disproportionate share regulations are established by the LDH and are subject to review and approval by the Centers for Medicare and Medicaid Services. The System has included approximately \$261,104,000 and \$243,595,000 for Medicaid disproportionate share revenues in net patient service revenues, for the years ended December 31, 2019 and 2018, respectively. At December 31, 2019 and 2018, respectively, approximately \$17,210,000 and \$30,978,000 of these revenues were not yet collected and therefore included in Supplemental Payments Receivable in the consolidated balance sheets.

During 2019 and 2018, the System received approximately \$14,766,000 and \$14,774,000 from the State in the form of Graduate Medical Education Supplement Payment.

Effective January 1, 2019, the System entered in an agreement with the Louisiana Quality Network (LQN) to facilitate payments to the System under the State of Louisiana's Medicaid Managed Care Quality Incentive Program (Program). The Louisiana Department of Health (LDH) amended its agreements with its MCOs to include gualitybased performance measures and quality-based outcomes. With the expected achievement of the defined quality measures, LDH will fund the MCOs, who in turn will fund LQN, for the Managed Care Incentive Payment (MCIP). For each measurement year, LDH will evaluate the performance relative to the specific quality measures. In the event LDH finds a deficiency in the accomplishment of those performance measures, there is the potential for recoupment of the MCIPs. Under the terms of the agreement with LQN, the System recognized estimated incentive payments for the year ended December 31, 2019, of approximately \$30,008,000, which is included within net patient service revenue and as a receivable within supplemental payments receivable at December 31, 2019.

Notes to Consolidated Financial Statements

Note 3. Patient Service Revenues (Continued)

Supplemental Payment Program (Continued)

Total supplemental payments receivable as of December 31, 2019 and 2018 is summarized as follows:

	 2019	2018
Full Medicaid Pricing and Upper Payment Limit Receivables	\$ 80,628,000	\$ 47,694,000
Managed Care Incentive Payment Receivable	30,008,000	-
Medicaid Disproportionate Share Receivable	17,210,000	30,978,000
Graduate Medical Education Receivable	 1,275,000	768,000
Total Supplemental Payments Receivable	\$ 129,121,000	\$ 79,440,000

Medicare

In general, the System is reimbursed under the Medicare Prospective Payment System (PPS) for acute care inpatient services provided to Medicare beneficiaries, and is paid a predetermined amount for these services based on the Diagnosis Related Group (DRG) assigned to the patient. However, supplemental settlement based on annual cost reports occurs later as described below.

The System qualifies as a disproportionate share provider and as a teaching hospital under the Medicare regulations. As such, the System receives additional payments for Medicare inpatients served.

Outpatient services rendered to Medicare program beneficiaries are generally reimbursed by the Outpatient Prospective Payment System (OPPS), which establishes a number of Ambulatory Payment Classifications (APC) for outpatient procedures in which the System is paid a predetermined amount for these procedures. However, supplemental settlement based on annual cost reports occurs later as described below.

Transaction prices related to Medicare revenues are more at risk of being increased or decreased in a period after the actual services were performed as described in the Third Party Settlements section below.

Managed Medicare

Medicare Advantage Plans are a type of Medicare health plan offered by a private company that contracts with Medicare to provide Part A and Part B benefits. Managed Medicare reimbursement plans are typically offered by Health Maintenance Organizations, Preferred Provider Organizations, Private Fee-for-Service Plans or Special Needs Plans. The System has entered into agreements with these organizations to provide services to subscribers covered under these plans.

Notes to Consolidated Financial Statements

Note 3. Patient Service Revenues (Continued)

Managed Medicare (Continued)

Inpatient and outpatient services rendered to managed care subscribers are reimbursed at prospectively determined rates per discharge, discounts from established charges, and prospectively determined daily rates. Transaction prices related to Managed Medicare revenues, generally, are more at risk of being increased or decreased in a period after the actual services were performed as described in the Third-Party Settlements section below.

Guarantor/Patient/Other

Generally, patients who are covered by third-party payors are responsible for patient responsibility balances, including deductibles and coinsurance, which vary in amount. The System estimates the transaction price for patients with deductibles and coinsurance based on historical experience and current market conditions. Current facts and historical patterns actually observed are used to estimate ongoing implicit price concessions.

Third-Party Settlements

As mentioned in Note 2, patient service revenue increased by approximately \$28,212,000 and \$8,054,000 in 2019 and 2018, respectively, due to changes in estimates resulting from the filing of cost reports; the removal of allowances previously estimated that are no longer necessary as a result of final settlements; years that are no longer subject to audits, reviews and investigations; revision if allowance estimates recorded in prior years relating to expected retroactive adjustments; and revisions based on updated information from the fiscal intermediary.

The table below shows the sources of patient service revenue for the years ended December 31st (in thousands):

		2019			2018	
	Inpatient	Outpatient	Total	Inpatient	Outpatient	Total
Medicaid	\$174,441	\$198,294	\$ 372,735	\$170,666	\$169,876	\$ 340,542
UPL	180,358	12,338	192,695	154,545	12,111	166,656
DSH	154,223	106,881	261,104	138,584	105,011	243,595
Medicare	191,703	76,858	268,561	160,250	79,592	239,841
Guarantor/Patient/ Other	942	7,005	7,947	1,734	7,360	9,094
Other Third-Party						
Commercial	110,223	156,889	267,112	104,287	158,966	263,253
Managed Medicare	127,352	109,961	237,313	108,706	103,639	212,345
Eldercare	12,982	-	12,982	14,277	-	14,277
NPSR	\$952,224	\$668,225	\$1,620,449	\$853,049	\$636,555	\$1,489,603

Notes to Consolidated Financial Statements

Note 4. Assets Limited as to Use

At December 31, 2019 and 2018, assets limited as to use are invested as allowed and consist of the following investment categories (in thousands):

	2019	2018		
Cash	\$ -	\$	67	
U.S. Government Securities	34		53,748	
Marketable Equity Securities	566,670		507,981	
Other Fixed Income Securities	458,769		411,923	
Corporate Bonds	819		760	
State of Israel Bonds	500		500	
Money Market Funds, Certificates of				
Deposit, and Commercial Paper	 5,514		7,809	
Total	\$ 1,032,306	\$	982,788	

The System has approximately \$8,150,000 in future commitments to current hedge fund managers. Some hedge fund managers have withdrawal restrictions established upon entering their funds which limit an investor's ability to withdraw amounts as a protection for their investments. There also may be fees associated with early withdrawal that generally lapse over defined time periods. These restrictions generally allow for quarterly withdrawals; however, in no case does the withdrawal limitation extend beyond one year.

Note 5. Derivative Instruments

The System entered into derivative instruments consisting of interest rate swap agreements.

At December 31, 2019, the instruments consist of the following:

Trade Date	Maturity		lotional Amount	Hedged Rate		Derivative Rate	Counterparty
August 15, 2005 (amended December 24, 2018)	January 1, 2023	\$1	1,945,000	6.125%		Variable rate: SIFMA Index plus a spread	Touro
April 24, 2015 (amended December 24, 2018)	October 1, 2023	\$ 4	0,500,000	3.900%		Variable rate: SIFMA Index plus a spread	Touro
April 1, 2014 (amended December 24, 2018)	October 1, 2023	\$ 12	5,000,000	5.50%	*	USD-LIBOR-BBA	Children's
April 1, 2014 (amended December 24, 2018)	October 1, 2021	\$ 12	8,000,000	5.50%	*	USD-LIBOR-BBA	Children's

* From the trade date to but not including October 1, 2019, 5.65%. From and including October 1, 2019 to the maturity date, 5.50%.

Notes to Consolidated Financial Statements

Note 5. Derivative Instruments (Continued)

At December 31, 2018, the instruments consist of the following:

Trade Date	Maturity	Notional Amount	Hedged Rate	Derivative Rate	Counterparty
August 15, 2005 (amended December 24, 2018)	January 1, 2023	\$ 14,785,000	6.125%	Variable rate based on SIFMA Index	Touro
April 24, 2015 (amended December 24, 2018)	October 1, 2023	\$ 40,500,000	3.900%	Variable rate based on SIFMA Index	Touro
April 1, 2014 (amended December 24, 2018)	October 1, 2023	\$ 125,000,000	5.65%	USD-LIBOR-BBA	Children's
April 1, 2014 (amended December 24, 2018)	October 1, 2021	\$ 128,000,000	5.50%	USD-LIBOR-BBA	Children's

Interest expense associated with the debt instruments was reduced by the realized gains and interest earnings from the swaps' effectiveness by approximately \$9,520,000 and \$10,299,000 in 2019 and 2018, respectively. At December 31, 2019 and 2018, certain of these agreements had carrying values (which approximates fair value) in an asset position of approximately \$2,854,000 and \$2,499,000, respectively, which were recorded in other receivables.

With respect to the derivative instruments held at December 31, 2019 and 2018, the System's exposure to credit-related losses in the event of nonperformance by counterparties is minimized because the counterparties are international banks with excellent credit ratings.

All derivative instruments are subject to market risk, which is the risk that future changes in market conditions may make an instrument less valuable or more onerous. Exposure to market risk is managed in accordance with risk limits set by the investment committee of the LCMC Board of Trustees and by monitoring performance by investment managers in accordance with specified investment guidelines.

Notes to Consolidated Financial Statements

Note 6. Leases

The following table presents the components of the System's right-of-use assets and liabilities related to leases and their classification in consolidated balance sheet at December 31, 2019 (in thousands):

Component of Lease	Consolidated		
Balances	Balance Sheet	Decem	nber 31, 2019
Assets			
Operating Lease Assets	Other Assets	\$	48,490
Liabilities			
Operating Lease Liabilities			
Current	Other Current Liabilities	\$	4,898
Long-Term	Other Long-Term Liabilities		44,403
Total Operating Lease Liabi	lities	\$	49,300

Operating lease expense of approximately \$5,924,000 is recorded in supplies and other expenses in the consolidated statement of operations for the year ended December 31, 2019. There were no variable lease expenses. The weighted average lease term of operating leases is 10.69 years and the weighted average discount rate is 3.0%, as of December 31, 2019. Operating cash outflows from operating leases approximate operating lease expense reported the year ended December 31, 2019.

Supplies and other expenses for the year ended December 31, 2019, also include approximately \$9,818,000 of short term operating lease expense on leases that do not fall under the guidance ASU 2016-02. For the year ended December 31, 2018, operating lease expense totaled approximately \$9,265,000.

Notes to Consolidated Financial Statements

Note 6. Leases (Continued)

Future maturities of operating lease liabilities at December 31, 2019 are presented in the following table (in thousands):

2020	\$	6,292	
2021		5,638	
2022		5,376	
2023		4,646	
2024		4,314	
Later Years		32,676	
Total Lease Payments		58,943	
Less: Imputed Interest		9,643	
Total Lease Obligations		49,300	
Less: Current Obligations	4,898		
Long-Term Lease Obligations	\$	44,403	

Note 7. Property, Plant, and Equipment

At December 31st, property, plant, and equipment consisted of the following (in thousands):

	2019	2018
Land and Land Improvements	\$ 62,408	\$ 61,934
Leasehold Improvements	1,442	1,442
Buildings	438,315	382,011
Fixed Equipment	159,200	157,064
Major Moveable Equipment	500,772	469,052
	 1,162,137	1,071,503
Less: Accumulated Depreciation	(699,700)	(642,018)
Construction in Progress	 185,217	94,418
Property, Plant and Equipment, Net	\$ 647,654	\$ 523,903

Depreciation expense on depreciable assets was approximately \$75,850,000 and \$52,281,000 for the years ended December 31, 2019 and 2018, respectively.

Notes to Consolidated Financial Statements

Note 8. Investments in Joint Ventures

In January 2015, Touro Infirmary's subsidiary, CCPI, exchanged consideration of \$44,100,000 for a 49% interest in Crescent City Surgical Center (CCSC). CCPI is able to exercise significant influence over the operations of CCSC. As such the investment is accounted for using the equity method. The income earned by CCPI for the years ended December 31, 2019 and 2018 is included within other operating revenues.

The System has invested in various other joint ventures through Touro Infirmary and West Jefferson. Summarized financial information for the System's equity investments in its joint ventures, in approximation, for 2019 present equity earnings of \$7,409,000, distributions of \$7,713,000, capital contributions of \$2,225,000, and total equity at December 31, 2019 of \$57,186,000. For the year ended December 31, 2018, equity earnings were \$7,538,000, distributions of \$13,333,000, and capital contributions of \$700,000. The total equity at December 31, 2018 was \$55,265,000.

Note 9. Line of Credit

UMCMC entered into a \$100,000,000 revolving line of credit agreement with J.P. Morgan Chase Bank, N.A. The advances bear interest from the borrowing date until they are paid in full, at a variable rate plus a margin, as defined in the agreement. The interest rate at December 31, 2019 and 2018 was 2.55% and 3.30%, respectively. Interest is payable quarterly on the first day of each January, April, July, and October.

In 2019, the agreement was amended to extend the maturity date to December 12, 2020. At December 31, 2019 and 2018, the amount outstanding on the line of credit was \$100,000,000. The line of credit is secured by the pledge of gross revenues from UMCMC and guarantees of LCMC and Children's. The lender to this borrowing has limited to \$15,000,000 the amount of new debt that may be incurred by UMCMC without the prior written consent of the lender.

Notes to Consolidated Financial Statements

Note 10. Bonds Payable

At December 31st, bonds payable consist of the following tax-exempt revenue and refunding bonds issued by the Louisiana Public Facilities Authority on behalf of Touro and LCMC (in thousands):

	2019	2018
Series 1993 Bonds Interest fixed at 6.125%, principal and interest payable annually through maturity on August 15, 2027.	\$ 11,945	\$ 14,785
Series 2015 Bonds Interest fixed at 3.90%, principal and interest payable annually beginning in 2020 through maturity in 2029.	40,500	40,500
Series 2015 A1 - Serial Bonds Interest fixed at 5.00%, payable semi-annually, beginning December 1, 2018. Principal payments begin June 1, 2036 through maturity on June 1, 2039.	27,515	27,515
Series 2015 A1 - Term Bonds Interest at 5% per annum, payable semi-annually, beginning December 1, 2018. Mandatory redemption beginning June 1, 2040 through maturity on June 1, 2045.	27,320	27,320
Series 2015 A1 - Term Bonds Interest at 4% per annum, payable semi-annually, beginning June 1, 2018. Mandatory redemption beginning June 1, 2040 through maturity on June 1, 2045.	25,000	25,000
Series 2015 A2 Bonds - Term Rate Mode Initial interest rate of 5.00% through June 1, 2025. Interest is payable semi-annually, beginning December 1, 2018 Mandatory redemption beginning June 1, 2036 through maturity on June 1, 2045.	75,140	75,140
Series 2015 A3 Bonds - Term Rate Mode Initial interest rate of 5.00% through June 1, 2023. Interest is payable semi-annually, beginning December 1, 2018. Mandatory redemption beginning June 1, 2036 through maturity of June 1, 2045.	27,095	27,095
Series 2017 Bonds - Index Rate Mode Initial Index Rate is SIFMA plus 0.65% (65 basis points). Interest is payable monthly beginning September 4, 2018. Mandatory sinking fund redemption beginning September 1, 2046		
through maturity on September 1, 2057.	 125,000	125,000
Plus: Unamortized Original Issue Premium	359,515	362,355
Less: Unamortized Original Issue Premium	19,176 (74)	20,077 (92)
Less: Debt Issuance Costs, Net of Amortization	(2,871)	(3,018)
	 375,746	379,322
Less: Current Maturities of Bonds Payable	 (3,350)	(2,840)
Bonds Payable - Long-Term	\$ 372,396	\$ 376,482

Notes to Consolidated Financial Statements

Note 10. Bonds Payable (Continued)

At December 31, 2019, scheduled repayments of principal and sinking fund installments to retire the bonds are as follows (in thousands):

2020	\$ 3,350
2021	4,610
2022	4,860
2023	3,870
2024	5,405
2025-2029	30,350
2030-2034	-
2035-2039	62,405
2040-2044	97,255
2045-2049	58,445
2050-2054	52,680
2055-2059	36,285
Thereafter	 -
Total	\$ 359,515

Note 11. Notes Payable

UMCMC entered into a trust indenture with the Bank of New York Mellon Trust Company relating to the issuance of the Series 2014 Notes totaling \$253,000,000. The notes were issued in two series: (i) Series 2014-A1 Notes in the principal amount of \$125,000,000 and (ii) Series 2014-A2 Notes in the principal amount of \$128,000,000. These notes are the general obligations of UMCMC and are secured by the trust estate (described below).

The Series 2014-A1 Notes and 2014-A2 Notes mature on April 1, 2024 and bear interest at a rate of 7.25%. Interest only is payable on these notes on April 1st and October 1st. UMCMC has established a debt service fund for holding funds sufficient to support the debt service on these notes.

As security for payment of these notes, UMCMC pledges and assigns: (i) a security interest in their debt service fund mentioned above, (ii) pledged revenues that includes all receipts, income, rents, royalties, benefits and other revenue from the operation of UMCMC's facilities, exclusive of revenue from donors that have a restriction as to the use of the revenue and exclusive of revenues where applicable law precludes the granting of a security interest in those revenues, and (iii) any and all property of every kind that may be subjected to the lien of the Trust Indenture. Collectively, these three elements define the trust estate.

Notes to Consolidated Financial Statements

Note 11. Notes Payable (Continued)

At December 31st, notes payable consists of the following (in thousands):

		2019	-	2018
Series 2014 Notes Payable Less: Debt Issuance Costs, Net of Amortization	\$	253,000 (512)	\$	253,000 (632)
Non-Current Portion of Notes Payable	\$	252,488	\$	252,368

Note 12. Employee Retirement Plans

Defined Contribution Plans

In 2016, the Louisiana Children's Medical Center Retirement Savings Plan (LCMCRS Plan) was formed by LCMC as a Section 403(b) defined contribution employee benefit plan.

During the course of 2016, the existing plans of Children's, CHMPC, Touro Infirmary, Woldenberg, UMCMC, and West Jefferson were merged into the LCMCRS Plan.

The employees of Children's, CHMPC, Touro Infirmary, Woldenberg, UMCMC, and West Jefferson became participants in the LCMCRS Plan at varying times during 2016, with the employees' deferrals together with any employer contributions being directed to the investment options in the LCMCRS Plan.

Employer contributions for LCMC, Touro Infirmary, UMCMC, West Jefferson, and LHAC are comprised of a contribution of 2% of each eligible employee's compensation, a qualified matching contribution of 50% on an eligible employee's contribution up to 4% of the employee's eligible earnings, and an employer discretionary contribution up to 3% of each participant's compensation. Contributions by these entities during the years ended December 31, 2019 and 2018, were approximately \$11,202,000 and \$10,543,000, respectively.

Through March 31, 2018, employer contributions for Children's were comprised of a contribution of 3% of each eligible employee's compensation, a qualified matching contribution of 50% on an eligible employee's contribution up to 7% of the employee's eligible earnings, and an employer discretionary contribution up to 3% of each participant's compensation. Beginning April 1, 2018, Children's moved to the System's structure described in the previous paragraph. Contributions by Children's during the years ended December 31, 2019 and 2018, were approximately \$3,516,000 and \$3,375,000, respectively.

Notes to Consolidated Financial Statements

Note 12. Employee Retirement Plans (Continued)

Defined Contribution Plans (Continued)

Through March 31, 2018, employer contributions for CHMPC are comprised of a contribution of 1.5% of each eligible employee's compensation, a qualified matching contribution of 50% on an eligible employee's contribution up to 7% of the employee's eligible earnings, and an employer discretionary contribution up to 3% of each participant's compensation. Beginning April 1, 2018, CHMPC moved to the System's structure described above. Contributions by CHMPC during the years ended December 31, 2019 and 2018, were approximately \$466,000 and \$383,000, respectively.

Eligible employees of Woldenberg who participate may make tax-deferred contributions; however, Woldenberg does not match any portion of the employees contributions nor does it make any discretionary contribution.

CCPI and NOPS sponsor their own 401(k) defined contribution employee benefit plan.

Employees of CCPI may contribute to the Plan through salary deferrals. CCPI makes qualified matching contributions of 100% of an eligible employee's contribution up to 3% of their eligible earnings, plus 50% of an eligible employee's contribution in excess of 3% of their eligible earnings up to 5% of their eligible earnings. Contributions by CCPI during the years ended December 31, 2019 and 2018, were approximately \$895,000 and \$856,000, respectively

NOPS employees, too, may contribute to the Plan through salary deferrals. Eligible employees receive a non-elective safe harbor contribution of 3% of their compensation. In addition, NOPS matches 100% of an eligible employee's contribution up to 2% of the employee's eligible earnings. Contributions by NOPS during the year ended December 31, 2019 and 2018 were approximately \$579,000 and \$547,000, respectively.

Defined Benefit Pension Plan

Through December 31, 2015, Touro Infirmary's defined benefit pension plan (the Plan) covers substantially all full-time employees. The Plan is noncontributory and provides benefits that are based on the participants' years of service and level of compensation. Through December 31, 2015, each participant is entitled to an account balance that grows each year with pay, transition, employer match, and interest credits. Effective January 1, 2016, the Plan was amended to eliminate pay credits and to eliminate the addition of participants. Pay credits shall not be credited with respect to any compensation that is earned after December 31, 2015. Further, an employee who is not a participant in the Plan on December 31, 2015 may not become a participant after December 31, 2015.

Touro's funding policy is based on the minimum and maximum funding standards under the Employee Retirement Income Security Act of 1974, as amended by the Pension Protection Act of 2006, as well as the Highway and Transportation Funding Act, as determined by its consulting actuaries.

Notes to Consolidated Financial Statements

Note 12. Employee Retirement Plans (Continued)

Defined Benefit Pension Plan (Continued)

The System's consolidated financial statements include net periodic pension expense of approximately \$367,000 and benefit of approximately \$190,000 for the years ended December 31, 2019 and 2018, respectively. Touro made contributions of \$-0- and \$800,000 during the years ended December 31, 2019 and 2018, respectively. As of December 31, 2019 and 2018, the System has unfunded liabilities associated with this plan totaling approximately \$10,723,000 and \$9,417,000, as of December 31, 2019 and 2018, respectively.

The tables that follow set forth the Plan's components of net periodic pension cost, change in projected benefit obligation, change in plan assets, funded status, and pension expense recognized by Touro Infirmary as of and for the years ended December 31, 2019 and 2018 using the projected unit credit method with salary progression (in thousands).

	2019		2018			
Change in Benefit Obligation						
Benefit Obligation at Beginning of Year	\$ 37,602	\$	42,320			
Service Cost	-		-			
Interest Cost	1,463		1,429			
Curtailment / Settlement	-		-			
Actuarial Loss (Gain)	4,192		(3,140)			
Benefits Paid	 (3,896)					
Benefit Obligation at End of Year	39,361		37,602			
Change in Plan Assets						
Fair Value of Plan Assets at Beginning of Year	28,185		32,582			
Actual Return on Plan Assets	4,349		(2,190)			
Benefits Paid	(3,896)		(3,007)			
Employer Contributions	 -		800			
Fair Value of Plan Assets at End of Year	 28,638		28,185			
(Underfunded) Status	\$ (10,723)	\$	(9,417)			
Net Periodic Pension Cost						
Service Cost	\$ -	\$	-			
Interest Cost	1,463		1,429			
Actuarial (Gain) Loss on Plan Assets	(4,349)		2,190			
Net Amortization	 3,253		(3,809)			
Net Periodic Cost (Benefit)	\$ 367	\$	(190)			

Notes to Consolidated Financial Statements

Note 12. Employee Retirement Plans (Continued)

Defined Benefit Pension Plan (Continued)

Included in net assets at December 31st, are the following amounts that have not yet been recognized in net periodic postretirement benefit cost (in thousands):

	2019	2018
Unrecognized Net Actuarial Loss Unrecognized Prior Service Cost	\$ 11,170 -	\$ 10,231
Total Accrued Benefit Cost	\$ 11,170	\$ 10,231

Amounts included in net assets at December 31, 2019, that are expected to be amortized into net periodic post-retirement cost during 2020 total approximately \$45,000.

Weighted-average assumptions used to determine projected benefit obligations at December 31st were as follows:

	2019	2018
Discount Rate, Obligation	3.10%	4.10%
Discount Rate, Periodic Cost	4.10%	3.50%
Expected Return on Plan Assets	7.00%	7.00%
Rate of Compensation Increase	N/A	N/A
Cash Balance Interest Credit Rate	3.00%	3.00%

The defined benefit pension plan asset allocation as of the measurement date (January 1st) and the target asset allocation, presented as a percentage of total plan assets, were as follows:

	2019	2018	Target Allocation
Domestic Equity	20.3%	18.2%	20%
International Equity	20.6%	19.9%	21%
Fixed Income	45.3%	45.2%	45%
Cash/Short-Term Fixed Income	9.8%	9.8%	10%
Liquid Absolute Return	0.0%	3.9%	0%
Real Assets	4.0%	3.0%	4%

The Plan invests in a diversified mix of traditional asset classes, including equities, government and corporate fixed income debt securities, and cash and cash equivalents. The Plan's overall allocation is based on mean variance optimization modeling using certain assumptions regarding expected return, risk, and correlations among various asset classes. Asset allocation analysis considers various potential outcomes and probabilities of returns given current capital markets assumptions.

Notes to Consolidated Financial Statements

Note 12. Employee Retirement Plans (Continued)

Defined Benefit Pension Plan (Continued)

As discussed in Note 2, the System uses a fair value hierarchy for valuation inputs.

The following tables set forth by level, within the fair value hierarchy, the Plan's investments at fair value as of December 31, 2019 and 2018 (in thousands):

2019	Level 1 Level 2			Total		
Domestic Equity	\$ 5,810	\$	-	\$	5,810	
International Equity	5,886		-		5,886	
Fixed Income	8,543		4,443		12,986	
Cash/Short-Term Fixed Income	2,797		-		2,797	
Real Assets	 1,159		-		1,159	
Total	\$ 24,195	\$	4,443	\$	28,638	
2018	Level 1	L	evel 2		Total	
Domestic Equity	\$ 5,130	\$	-	\$	5,130	
International Equity	5,593		-		5,593	
Fixed Income	8,517		4,234		12,751	
Cash/Short-Term Fixed Income	2,755		-		2,755	
Liquid Absolute Return	1,099		-		1,099	
Real Assets	 857		-		857	
Total	\$ 23,951	\$	4,234	\$	28,185	

In general, equity securities (both value and growth and active and passive) are utilized to provide expected returns above those of fixed income securities. Fixed income securities are utilized to provide a more stable and less volatile series of returns. The fixed income portfolio contains only securities considered investment grade by maintaining a rating of at least BAA/BBB by Moody's or Standard and Poor's rating agencies.

Professional money managers are delegated the day-to-day responsibility of managing individual portfolios within the context of certain diversification guidelines and to certain performance benchmark standards.

The Plan's investment consultant provides quarterly performance reports to evaluate the achievement of overall return expectations of total investments as well as each manager's contribution, both on the basis of absolute and relative performance standards.

Notes to Consolidated Financial Statements

Note 12. Employee Retirement Plans (Continued)

Defined Benefit Pension Plan (Continued)

The Plan's overall asset allocation is reviewed periodically to conform to current market conditions and expectations with regard to overall capital markets assumptions. Historical return patterns and correlations, expected return risk premium, and other multifactor considerations are utilized in the development of overall capital markets assumptions for the purpose of the Plan's asset allocation determinations.

Touro Infirmary expects to make contributions of approximately \$2,361,000 to the defined benefit pension plan in 2020.

At December 31, 2019 and 2018, Touro Infirmary's plan had accumulated benefit obligations of approximately \$39,361,000 and \$37,602,000, respectively.

Future benefit payments expected to be paid in each of the next five fiscal years and in the aggregate for the following five years as of December 31, 2019, are as follows (in thousands):

2020	\$ 1,850
2021	1,630
2022	1,860
2023	1,940
2024	1,840
2025-2029	 9,080
Total	\$ 18,200

Executive Benefit Plan

The System sponsors has benefits for both current and former members of senior management. These include supplemental executive retirement plans, deferred compensation plans and an executive employment retention plan, with specific vesting dates, providing the executive with tax deferral opportunities. The liabilities associated with these plans total approximately \$920,000 and \$850,000 at December 31, 2019 and 2018, respectively. These liabilities are presented on the consolidated balance sheets within accrued salaries and benefits and employee benefits. In addition, Children's and LCMC sponsor a 457(b)-investment account that can be utilized by senior management and certain employee medical providers. As of December 31, 2019, and 2018, the System's total liability for these plans is approximately \$9,325,000 and \$6,446,000, respectively, and is included in accrued salaries and benefits on the consolidated balance sheets. Related assets of approximately \$9,325,000 and \$6,446,000, at December 31, 2019 and 2018, respectively, are recorded in other assets on the consolidated balance sheets to fully settle these plan liabilities.

Notes to Consolidated Financial Statements

Note 13. Concentrations of Credit Risk

Patient accounts receivable are stated at estimated net realizable value. The System grants credit without collateral to its patients, most of who are Gulf South region residents and are insured under third-party payor agreements.

The mix of receivables from patients and third-party payors at December 31st, was as follows:

	2019	2018
Medicare	26 %	28 %
Medicaid	27	26
Managed Care	43	40
Patients	3	5
Workers' Compensation	1	1
Total	100 %	100 %

Receivables from government-related programs (i.e., Medicare and Medicaid) represent the only concentrated group of credit risk for the System, and management does not believe that there are any credit risks associated with these government programs. Commercial and managed care receivables consist of receivables from various payors involved in diverse activities and subject to differing economic conditions and do not represent any concentrated credit risks to the System.

The System records implicit pricing concessions for estimated losses resulting from a payors inability to make payments on accounts. The System estimates the implicit pricing concessions based on historical write-offs and the aging of the accounts. Management continually monitors and adjusts its allowances associated with its receivables.

The System periodically maintains cash in bank accounts in excess of insured limits. The System has not experienced any losses and does not believe that significant credit risk exists as a result of this practice.

Note 14. Net Assets with Donor Restrictions

Net assets with donor restrictions are restricted for purposes specific to healthcare programs and facilities totaling approximately \$6,023,000 at December 31, 2019, and \$5,324,000 at December 31, 2018, respectively.

They are also comprised of endowments that are subject to the spending policy of the System totaling approximately \$5,992,000 at December 31, 2019, and \$5,905,000 at December 31, 2018, respectively.

Notes to Consolidated Financial Statements

Note 14. Net Assets with Donor Restrictions (Continued)

Net assets were released from donor restrictions by incurring expenses satisfying the restricted purposes or by occurrence of other events specified by donors. The assets whose purpose was met and released totaled approximately \$2,311,000 and \$9,380,000 for the years ended December 31, 2019 and 2018, respectively. During the year ended December 31, 2018, net assets were also released from restriction when a donor released their endowment restriction of \$2,000,000.

Note 15. Endowment

The State of Louisiana enacted the Uniform Prudent Management of Institutional Funds Act (UPMIFA) effective August 15, 2010, the provisions of which apply to endowment funds existing on or established after that date. The net assets classified as perpetual in nature have been determined to meet the definition of endowment funds under UPMIFA.

The System holds donor-restricted endowment funds established primarily to fund specified activities for and within the System and the medical community as a whole. As required by accounting principles generally accepted in the United States of America, net assets associated with endowment funds are classified and reported based on the existence or absence of donor-imposed restrictions.

The Board has interpreted the State of Louisiana's UPMIFA as requiring the preservation of the fair value at the original gift date of the donor-restricted endowment funds absent explicit donor stipulations to the contrary. As a result of the interpretation, the System classifies as net assets with donor restrictions - perpetual in nature (a) the original value of gifts donated as an endowment, (b) the original value of subsequent endowment gifts, and (c) accumulations to the endowments made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund. The remaining portion of the donor-restricted endowment fund that is not classified as perpetual in nature are classified net assets with donor restrictions - purpose restricted until those amounts are appropriated for expenditure by the System in a manner consistent with the standard of prudence prescribed in UPMIFA.

In accordance with UPMIFA, the System considers the following factors in making a determination to appropriate or accumulate donor-restricted endowment funds: (1) the duration and preservation of the various funds, (2) the purpose of the donor-restricted endowment funds, (3) general economic conditions, (4) the possible effect of inflation and deflation, (5) the expected total return from income and the appreciation of investments, (6) other resources of the System, and (7) the System's investment policies.

Notes to Consolidated Financial Statements

Note 15. Endowment (Continued)

Endowment Investment and Spending Policies: The System has adopted investment and spending policies for endowment assets to achieve a disciplined, consistent management philosophy that accommodates reasonable and probable events. Preservation of capital and return on investment are of primary importance. The primary investment objective is to preserve financial assets generated through donor gifts, so that the proceeds may be distributed for the purposes intended by the donors and to the benefit of the System, at a level of risk deemed acceptable by the LCMC investment committee. To satisfy its long-term rate-of-return objectives, the System relies on a strategy outlined by its investment policy statement and includes purchases of bonds, stocks, and cash and cash equivalents.

The System's Endowment Net Asset Composition by fund type as of December 31, 2019, is as follows (in thousands):

	W	With Donor Restrictions					
	Donor Restrictions		Pu	Purpose Perpe		ual in Nature	Total
Donor-Restricted Endowment Funds Undesignated Funds	\$	-	\$	-	\$	5,992 -	\$ 5,992 -
Total	\$	-	\$	-	\$	5,992	\$ 5,992

A summary of the changes in the System's Endowment Net Assets for the year ended December 31, 2019, is as follows (in thousands):

	W	ithout	ut With Donor Restrictions				
	Donor F	Restrictions	Pu	rpose	Perpet	ual in Nature	Total
Net Assets, Beginning of Year	\$	-	\$	-	\$	5,905	\$ 5,905
Contributions		-		-		87	87
Investment Return							
Investment Income		-		-		-	-
Net Appreciation (Realized and Unrealized)		-		-		-	-
Total Investment Return		-		-		-	
Released from Restriction		-		-		-	-
Appropriation of Endowment Net Assets for Expenditure		-		-		-	
Net Assets, End of Year	\$	-	\$	-	\$	5,992	\$ 5,992

Notes to Consolidated Financial Statements

Note 15. Endowment (Continued)

The System's Endowment Net Asset Composition by fund type as of December 31, 2018, is as follows (in thousands):

	Wi	With Donor Restrictions						
	Donor Restrictions		Purpose		Perpetual in Nature		Total	
Donor-Restricted Endowment Funds Undesignated Funds	\$	-	\$	-	\$	5,905 -	\$	5,905 -
Total	\$	-	\$	-	\$	5,905	\$	5,905

A summary of the changes in the System's Endowment Net Assets for the year ended December 31, 2018, is as follows (in thousands):

					nor Res		
	Donor I	Restrictions	Pu	rpose	Perpet	tual in Nature	Total
Net Assets, Beginning of Year	\$	(120)	\$	142	\$	7,843	\$ 7,865
Contributions		-		-		62	62
Investment Return							
Investment Income		-		-		-	-
Net Appreciation (Realized and Unrealized)		-		-		-	-
Total Investment Return		-		-		-	-
Released from Restriction		120		(142)		(2,000)	(2,022)
Appropriation of Endowment Net Assets for Expenditure		-		-		-	
Net Assets, End of Year	\$	-	\$	-	\$	5,905	\$ 5,905

Notes to Consolidated Financial Statements

Note 16. Assets Held in Trust

Children's has been named the income beneficiary of a separate trust. Because the assets of the trust are not controlled by Children's and Children's does not have an irrevocable right to receive the income earned on the trust's assets, they are not included in Children's financial statements. The assets had a market value of approximately \$4,199,000 and \$4,006,000 at December 31, 2019 and 2018, respectively. Distributions of income are made at the discretion of the trustee. For the years ended December 31, 2019 and 2018, Children's recorded contribution income of approximately \$153,000 and \$141,000, respectively, received from the trust.

Note 17. Functional Expenses

The System provides general health care services, both inpatient and outpatient, to patients in the Gulf South region. For the years ended December 31, 2019 and 2018, expenses related to providing these services are as follows (in thousands):

				Program	n				_								
December 24, 2040	Adult	Pediatric	Medical Education	Physicians Group	Senior Care		minations	Total		nagement d General	-	minations	Total	F	ndraisin	_	Total
December 31, 2019 Operating Expenses	Adult	Pediatric	Education	Group	Care	EIII	minations	Iotai	an	d General	EII	minations	Iotai	Fur	naraising	g	Total
Employee Compensation and																	
Benefits	\$ 176.718	\$ 112.496	¢ 1/0 0/2	\$ 115,258	\$ 9.55	7 ¢	(7.474)	\$ 555.398	\$	124.760	¢	(1.672)	\$ 123,088	¢	1.157	\$	679.643
Purchased Services	67,186	19,568	11,236	11,259	\$ 9,55 2.71	•	(2,632)	109,329	φ	223,838	φ	(121,095)	102,743	φ	2.244	•	214,316
Professional Fees	33.001	44.351	164.063	9.675	2,71		(11,707)	239.433		17.082		(121,033)	17.082		410		256.925
Supplies and Other Expenses	133.147	52,761	202,930	10.728	1.73		(1,313)	399,983		55,735		(3,216)	52,519		1.165		453,667
Depreciation and Amortization	24,662	14.532	202,550	1.178	95		(1,515)	41.331		50,854		(17.317)	33,537		123		74,991
Interest	24,002	-	50	-		,		41,551		20,825		-	20,825		-		20,875
increat	\$ 434,714	\$ 243,708	\$ 527,122	\$ 148,098	\$ 15,00	3\$	(23,126)	\$1,345,524		493,094	\$	(143,300)		\$	5,099	\$	1,700,417
Non-operating Expenses																	
Community Support	\$ 3.124	\$ 17,002	\$ 2.645	s -	\$ -	s	-	\$ 22,771	\$	-	\$		s -	\$	-	\$	22,771
				Program					_								
December 31, 2018	Adult	Pediatric	Medical Education	Physicians	Senior	Flir	minations	Total		nagement d General	Fli	minations	Total	Bur	odraisin	a	Total
	Adult	Pediatric	Medical Education			Elir	minations	Total		nagement d General	Eli	minations	Total	Fur	ndraising	g	Total
Operating Expenses	Adult	Pediatric		Physicians	Senior	Elir	minations	Total			Eli	minations	Total	Fun	ndraising	g	Total
	Adult \$ 181.012		Education	Physicians Group	Senior Care		minations (7.431)		an				Total \$ 118.019		ndraising 954		
Operating Expenses Employee Compensation and			Education	Physicians Group	Senior Care	3\$			an	d General						\$	642,353
Operating Expenses Employee Compensation and Benefits	\$ 181,012	\$ 97,664	Education \$ 140,284	Physicians Group \$ 103,301	Senior Care \$ 8,55	3 \$ 9	(7,431)	\$ 523,382	an \$	d General 118,934		(915)	\$ 118,019		954	\$	642,353 217,925
Benefits Purchased Services	\$ 181,012 65,599	\$ 97,664 17,237	Education \$ 140,284 9,757	Physicians Group \$ 103,301 10,688	Senior Care \$ 8,55 2,40	3 \$ 9 7	(7,431)	\$ 523,382 105,691	an \$	d General 118,934 248,107		(915)	\$ 118,019 111,094		954 1,140	\$	642,353 217,925 208,522
Operating Expenses Employee Compensation and Benefits Purchased Services Professional Fees	\$ 181,012 65,599 36,574	\$ 97,664 17,237 42,423	Education \$ 140,284 9,757 122,046	Physicians Group \$ 103,301 10,688 7,262	Senior Care \$ 8,55 2,40 5	3 \$ 9 7	(7,431) - (12,923)	\$ 523,382 105,691 195,440	an \$	d General 118,934 248,107 12,794		(915) (137,013) -	\$ 118,019 111,094 12,794		954 1,140 288	\$	642,353 217,925 208,522 438,093
Operating Expenses Employee Compensation and Benefits Purchased Services Professional Fees Supplies and Other Expenses	\$ 181,012 65,599 36,574 113,452	\$ 97,664 17,237 42,423 45,149	Education \$ 140,284 9,757 122,046 211,954	Physicians Group \$ 103,301 10,688 7,262 19,264	Senior Care \$ 8,55 2,40 5 1,32	3 \$ 9 7	(7,431) - (12,923) (2,262)	\$ 523,382 105,691 195,440 388,883	an \$	d General 118,934 248,107 12,794 49,808		(915) (137,013) - (1,185)	\$ 118,019 111,094 12,794 48,623		954 1,140 288 587	\$	642,353 217,925 208,522 438,093 65,915
Operating Expenses Employee Compensation and Benefits Purchased Services Professional Fees Supplies and Other Expenses Depreciation and Amortization	\$ 181,012 65,599 36,574 113,452	\$ 97,664 17,237 42,423 45,149 13,497 -	Education \$ 140,284 9,757 122,046 211,954 19,302 50	Physicians Group \$ 103,301 10,688 7,262 19,264	Senior Care \$ 8,55 2,40 5 1,32 95 -	3 \$ 9 5 5	(7,431) - (12,923) (2,262) (10,697) -	\$ 523,382 105,691 195,440 388,883 54,213	an \$	d General 118,934 248,107 12,794 49,808 11,604	\$	(915) (137,013) - (1,185) - -	\$ 118,019 111,094 12,794 48,623 11,604	\$	954 1,140 288 587 97 -	\$	642,353 217,925 208,522 438,093
Operating Expenses Employee Compensation and Benefits Purchased Services Professional Fees Supplies and Other Expenses Depreciation and Amortization	\$ 181,012 65,599 36,574 113,452 30,157 -	\$ 97,664 17,237 42,423 45,149 13,497 -	Education \$ 140,284 9,757 122,046 211,954 19,302 50	Physicians Group \$ 103,301 10,688 7,262 19,264 998 -	Senior Care \$ 8,55 2,40 5 1,32 95 -	3 \$ 9 5 5	(7,431) - (12,923) (2,262) (10,697) -	\$ 523,382 105,691 195,440 388,883 54,213 50	an \$	d General 118,934 248,107 12,794 49,808 11,604 19,661	\$	(915) (137,013) - (1,185) - -	\$ 118,019 111,094 12,794 48,623 11,604 19,661	\$	954 1,140 288 587 97 -	\$	642,353 217,925 208,522 438,093 65,915 19,710
Operating Expenses Employee Compensation and Benefits Purchased Services Professional Fees Supplies and Other Expenses Depreciation and Amortization	\$ 181,012 65,599 36,574 113,452 30,157 -	\$ 97,664 17,237 42,423 45,149 13,497 -	Education \$ 140,284 9,757 122,046 211,954 19,302 50	Physicians Group \$ 103,301 10,688 7,262 19,264 998 -	Senior Care \$ 8,55 2,40 5 1,32 95 -	3 \$ 9 5 5	(7,431) - (12,923) (2,262) (10,697) -	\$ 523,382 105,691 195,440 388,883 54,213 50	an \$	d General 118,934 248,107 12,794 49,808 11,604 19,661	\$	(915) (137,013) - (1,185) - -	\$ 118,019 111,094 12,794 48,623 11,604 19,661	\$	954 1,140 288 587 97 -	\$	642,353 217,925 208,522 438,093 65,915 19,710

Note 18. Fair Value of Financial Instruments

The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate fair value due to their short-term nature.

Notes to Consolidated Financial Statements

Note 18. Fair Value of Financial Instruments (Continued)

Assets and liabilities measured at fair value on a recurring basis at December 31, 2019, are summarized below (in thousands):

Assets	Level 1 Level 2 Level 3							Total air Value
Marketable Equity Securities	\$	498,591	\$	-	\$	-	\$	498,591
U.S. Government Securities		1		-		-		1
Corporate Bonds		-		819		-		819
Other Fixed Income Securities		191,065		-		28,175		219,239
Money Market Funds		5,514		-		-		5,514
State of Israel Bonds		-		500		-		500
Interest Rate and Basis Swaps		-		2,854		-		2,854
Investments Measured								
at Fair Value		695,170		4,173		28,175		727,517
Investments Measured at NAV ^(a)								310,249
Total Investments at Fair Value							\$	1,037,766

(a) In accordance with Subtopic 820-10, certain investments that were measured at net asset value per share (or its equivalent) have not been classified in the fair value hierarchy.

Assets and liabilities measured at fair value on a recurring basis at December 31, 2018, are summarized below (in thousands):

Assets	Level 1 Level 2 Level 3							Total Fair Value		
Cash	\$	67	\$	-	\$	-	\$	67		
Marketable Equity Securities		444,376		-		-		444,376		
Corporate Bonds		-		760		-		760		
Other Fixed Income Securities		181,571		-		25,162		206,733		
Money Market Funds		7,809		-		-		7,809		
State of Israel Bonds		-		500		-		500		
Interest Rate and Basis Swaps		-		2,499		-		2,499		
Investments Measured										
at Fair Value		633,823		3,759		25,162		662,744		
Investments Measured at NAV ^(a)								325,112		
Total Investments at Fair Value							\$	987,856		

(a) In accordance with Subtopic 820-10, certain investments that were measured at net asset value per share (or its equivalent) have not been classified in the fair value hierarchy.

Notes to Consolidated Financial Statements

Note 18. Fair Value of Financial Instruments (Continued)

The changes in investments measured at fair value for which the System has used Level 3 inputs to determine fair value for the year ended December 31, 2019, are as follows (in thousands):

	Level 3 Beginning Balance January 1,			lized and realized		chases, es, and		ransfers //or (Out)		el 3 Ending ce December
		2019	Gains	s (Losses)	Sett	lements	of L	evel 3.	3	31, 2019
Other Fixed Income Securities	\$	25,162	\$	1,120	\$	1,893	\$	-	\$	28,175

The System's measurements of fair value are made on a recurring basis and their valuation techniques for assets and liabilities recorded at fair value are as follows:

Investments - The fair value of investment securities is the market value based on quoted market prices, when available, or market prices provided by recognized broker dealers. If listed prices or quotes are not available, fair value is based upon externally developed models that use unobservable inputs due to the limited market activity of the investment.

Interest Rate and Basis Swap Agreements - The fair values of these agreements represent the estimated amount the System would pay to terminate these agreements at the reporting date, taking into account current interest rates and credit worthiness of the counterparty and the System.

Note 19. Commitments and Contingencies

The System has certain pending and threatened litigation and claims incurred in the ordinary course of business; however, management believes that the probable resolution of such contingencies will not exceed the System's recorded reserves or insurance coverage, and will not materially affect the consolidated financial position, results of operations, changes in net assets, or cash flows of the System.

The health care industry is subject to numerous laws and regulations of federal, state and local governments. These laws and regulations include, but are not necessarily limited to, matters such as licensure, accreditation, government health care program participation requirements, and reimbursement for patient services. Government activity has continued with respect to investigations and allegations concerning possible violations of fraud and abuse statutes and regulations by health care providers. Violations of these laws and regulations could result in expulsion from government health care programs together with the imposition of significant fines and penalties, as well as significant repayments for patient services previously billed. Management believes that the System is in compliance with fraud and abuse, as well as other applicable government laws and regulations. Compliance with such laws and regulations can be subject to future government review and interpretation as well as regulatory actions unknown or unasserted at this time.

Notes to Consolidated Financial Statements

Note 19. Commitments and Contingencies (Continued)

To ensure accurate payments to providers, the Tax Relief and Healthcare Act of 2006 mandated the Centers for Medicare & Medicaid Services (CMS) to implement so-called Recovery Audit Contractor (RAC) and Medicaid Integrity Contractor (MIC) programs on a permanent and nationwide basis. The programs use RACs and MICs to search for potentially improper Medicare and Medicaid payments that may have been made to health care providers that were not detected through existing CMS program integrity efforts. A RAC or MIC may reopen an initial determination made on a claim between one and four years from the date of the initial determination when good cause exists.

The System will deduct from revenue amounts assessed under the RAC and MIC audits after the assessment and appeals process is complete until such time that estimates of net amounts due can be reasonably estimated. RAC and MIC assessments against the System are anticipated; however, the outcome of such assessments is unknown and cannot be reasonably estimated. Management has determined RAC and MIC assessments to be insignificant to date.

Operating UMC

As mentioned in Note 1, UMCMC has assumed responsibility for operating UMC under the terms of a CEA. The UMC CEA has an initial term of five years and will automatically renew for five year terms, unless UMCMC provides at least two hundred seventy days' advance notice of its intent not to renew. The UMC CEA may terminate prior to the expiration of its term under the following conditions: (a) upon the mutual agreement of all parties; (b) there is a change in law that has a material adverse effect on the parties; or (c) expiration of the leases discussed further within this footnote.

Separate and apart from the aforementioned conditions, the UMC CEA also provides that LCMC shall be allowed to withdraw as a member of UMCMC prior to the expiration of the term of the UMC CEA. LCMC may withdraw as a member, without cause, upon providing sixty (60) days advance written notice to LSU; however, LCMC must act in good faith and with full consideration of UMCMC to be financially viable and sustainable, which determination will be made by the LCMC Board of Trustees only after a process that provides an opportunity for consultation and input by LSU and Tulane, as well as other academic partners, provided that the process will not delay or extend the 60 day period.

The UMC CEA became effective May 29, 2013.

Notes to Consolidated Financial Statements

Note 19. Commitments and Contingencies (Continued)

Leases with UMC

With regards to the UMC CEA mentioned in Note 1, UMCMC has entered into multiple lease agreements.

Effective May 29, 2013, UMCMC entered into an Amended and Restated Master Hospital Lease Agreement with LSU for the leasing of UMC as later amended. Beginning when the UMCMC took occupancy of UMC, UMCMC is obligated to minimum annual rental payments of approximately \$69,410,000.

The term of the UMC lease will be five years which will automatically renew for seven periods of five years each, for a total of thirty-five additional years, unless notice of non-renewal is provided at least 270 days before the end of the then current term. The annual rent payments for leasing UMC is subject to increase annually; however, that increase is limited to no more than 5% than the rent in the previous year. The annual lease payments for UMC will be reviewed and adjusted to the Fair Market Rental Value, as defined, every twenty years.

The Amended and Restated Master Hospital Lease Agreement required UMCMC to make advance lease payments towards the facility rental. Of this total, \$110,000,000 is a prepayment of a portion of the future UMC rent payments, excluding UMC's ambulatory care building and its garage. UMCMC will receive an annual credit of approximately \$5,500,000 against its rent obligation for UMC, for each of the first twenty years of the UMC lease term. The remaining \$143,000,000 represents all future rent payments for UMC's ambulatory care building and its garage. This will be amortized over the forty year term of the UMC lease.

In 2015 and 2016, UMCMC made amendments to the Amended and Restated Master Hospital Lease Agreement which allowed UMCMC to continue to occupy portions of the Interim LSU Hospital facility for the remainder of the lease term at an annual amount of \$1,326,000.

These advance payments are included within prepaid expenses on the consolidated balance sheets, as discussed in Note 2. These payments were funded by the Series 2014 Notes mentioned in Note 11.

Payment of rent by UMCMC under the Amended and Restated Master Hospital Lease Agreement is guaranteed by LCMC as long as they are the sole member of UMCMC.

Notes to Consolidated Financial Statements

Note 19. Commitments and Contingencies (Continued)

Leases with UMC (Continued)

In relation to the Amended and Restated Master Hospital Lease agreement, UMCMC entered into a Right of Use, Possession and Occupancy agreement whereby UMCMC is granted the right to use and occupy the land and surface improvements for allowing the leased buildings and future buildings and other improvements to be located on the land, together with vehicular and pedestrian access to and from the leased buildings and future improvements, parking and related uses. This agreement commences on the date that the UMC facility lease commences and shall only terminate and expire when the UMC facility lease expires.

Effective May 29, 2013, UMCMC also entered into an Equipment Lease for an initial term of ten years with two separate and successive options to renew for a period of five years. UMCMC is responsible for lost and stolen equipment that is being leased and the cost associated with either replacing that equipment or reimbursing the lessor for the fair market value of that equipment. UMCMC has substantial reporting requirements to the Louisiana Property Assistance Agency and the State's Legislative Auditor under this equipment lease.

Rent expense under the above Amended and Restated Master Lease and Equipment Lease totaled approximately \$74,607,000 and \$89,557,000 for the years ended December 31, 2019 and 2018, respectively.

In projecting minimum annual lease payments, UMCMC included a growth factor to its annual rents, calculated rent for UMC lease for only the first twenty years of its lease due to the provision of that rent being reviewed and adjusted to the Fair Market Rental Value, and included the application of the advance lease payment mentioned above.

Minimum annual rental payments, as of December 31, 2019 for the above mentioned leases, are as follows (in thousands):

2020	\$ 78,588
2021	71,069
2022	71,540
2023	71,310
2024	71,317
Thereafter	 792,357
Total	\$ 1,156,181

Notes to Consolidated Financial Statements

Note 19. Commitments and Contingencies (Continued)

Operating West Jefferson

As mentioned in Note 1, West Jefferson was formed for the purpose of operating assets leased to it by the District under the terms of a CEA and a Master Hospital Lease. The WJ CEA is entered into by West Jefferson, LCMC and the District and shall remain in effect for an initial term of 45 years, with an option to renew for up to two additional 15 year terms.

Terms of the WJ CEA

The WJ CEA provides for a series of transactions between West Jefferson, LCMC and the District (Parties) including:

- The District leasing to West Jefferson substantially all of the hospital real property owned by the District pursuant to the Master Hospital Lease;
- West Jefferson assuming the leases for the hospital real property leased by the District pursuant to the terms and conditions of the WJ CEA;
- West Jefferson assuming responsibility for hospital operations during the term;
- West Jefferson leasing the equipment owned by the District that is used in connection with the facilities pursuant to the Master Hospital Lease;
- LCMC committing that an aggregate of \$340,000,000 will be expended for capital expenditures over the 15 year commitment period to support the operations of West Jefferson and the facilities;
- West Jefferson and LCMC committing to supporting the clinical and research missions of the facilities; and
- The Parties entering into such other or additional transactions as they mutually agree may be necessary, referred to as contemplated transactions.

Consideration and Payments

The total consideration to be provided by West Jefferson to the District in connection with the Master Hospital Lease and the contemplated transactions, shall be the sum of:

- \$200,000,000 which includes the prepaid rent under the Master Hospital Lease;
- The potential for an additional \$20,000,000 of Performance Consideration;
- The assumption of post-closing obligations under the assigned assets;
- The District's right to retain certain cash, the investments and the trustee held funds; and
- The assignment and assumption and allocation between West Jefferson and the District of the Final Working Capital.

The Initial Consideration of \$200,000,000 was paid upon closing on September 30, 2015. Also paid upon closing was Specified Working Capital in the amount of \$27,224,000. On February 8, 2018, the specified working capital was finalized.

Notes to Consolidated Financial Statements

Note 19. Commitments and Contingencies (Continued)

Operating West Jefferson (Continued)

Consideration and Payments (Continued)

The performance consideration was to be paid to the District for foreseeable steady financial performance of the hospital business, with payments of \$6,667,000 per year for each of the first three years of the term with the payment due no later than 90 days following the last day of such performance year. The System's payment may be reduced should the Operating EBIDA, as defined, of West Jefferson be less than 7.5% of the Performance Consideration for that Performance Year. In that event, the Performance Consideration may be offset, at the discretion of West Jefferson, by the Indigent Costs for such Performance Year, up to a maximum offset of \$20,000,000 in the aggregate for the first three years of the term of the WJ CEA. The System concluded that it had not met the financial performance requirement as outlined above for the performance year ended December 31, 2018. As a result, there was no liability recorded on the consolidated balance sheets. This requirement expired during the year ended December 31, 2018.

Capital Commitments

As mentioned above, LCMC is committed to expending \$340,000,000 on capital expenditures. LCMC and West Jefferson covenant that during the term, but ending on the 15 year anniversary of the closing date of September 30, 2015, a minimum of \$340,000,000 shall be expended for the capital expenditures for the facilities and for other related health care projects. During the term, an aggregate of (a) \$95,000,000 shall be expended within the first five years of the commitment period, (b) \$210,000,000 aggregate portion shall be expended within first 10 years of the commitment period and (c) the full amount of the commitment funds shall have been expended prior to the expiration of the commitment period. Children's guarantees to the District, to the extent necessary, that LCMC shall have sufficient funds to fulfill its obligations relative to this capital commitment.

Community Benefit Payments

The WJ CEA further requires that West Jefferson make additional payments to the District in the aggregate amount of \$3,150,000 for use at the District's discretion for items the District deems beneficial to the community. As of December 31, 2018, these additional amounts had been fully paid.

Notes to Consolidated Financial Statements

Note 19. Commitments and Contingencies (Continued)

New Orleans East Hospital (NOEH)

On April 1, 2014, a CEA (NOEH CEA) was entered into between Parish Hospital Service District for Parish of Orleans, Louisiana Children's Medical Center and Touro Infirmary. Louisiana Children's Medical Center and Touro Infirmary are collectively referred to as the Joint Parties throughout the NOEH CEA.

The NOEH CEA provides that the Joint Parties will manage and be responsible for the day-to-day operations of a 50 bed public hospital and emergency department doing business as NOEH. Touro Infirmary will serve in the primary role of managing and being responsible for the day-to-day operations of NOEH and to provide supplemental operational support for NOEH to support and enhance the continuity and viability of NOEH's operations for the citizens of Eastern New Orleans.

Under the NOEH CEA, the Joint Parties are obligated for: (i) employing or contracting with those required to operate NOEH; (ii) providing comprehensive administrative, professional, operational, revenue cycle and financial management of NOEH; (iii) obtaining and maintaining the appropriate licenses, software and hardware and corresponding support services related to those technology systems; and (iv) assisting NOEH in recruiting medical staff. The agreement commenced on the Effective Date, as defined, and will expire June 30, 2029, with an option to renew for up to 10 years.

So long as a mortgage on Parish Hospital Service District for Parish of Orleans's property is insured or held by the Secretary of HUD, the Secretary may make a written request to Parish Hospital Service District for Parish of Orleans and the Joint Parties to terminate the NOEH CEA with or without cause.

Parish Hospital Service District for Parish of Orleans shall pay to the Joint Parties a fee that is comprised of annual management, revenue cycle management, and direct and indirect operating components. Parish Hospital Service District for Parish of Orleans and the Joint Parties have agreed that operating revenues of NOEH, as defined, shall be the only source of funds for paying the fee.

The Joint Parties may also terminate the NOEH CEA prior to the expiration of its term; should the accumulated and unpaid fees and operational obligations of the Joint Parties reach \$12,000,000, the Joint Parties are relieved of performing further their operational obligations.

Through the NOEH CEA, the System has recognized revenue of approximately \$3,071,000 and \$2,832,000 for the years ended December 31, 2019 and 2018, respectively, which is included within other operating revenues on the System's consolidated statements of operations. At December 31, 2019 and 2018, Parish Hospital Service District for Parish of Orleans owes the System approximately \$18,803,000 and \$14,673,000, respectively, for both the revenue recognized as well as direct costs incurred by the System on behalf of Parish Hospital Service District for Parish of Orleans. This amount is included within current other receivables on the System's consolidated balance sheets.

Notes to Consolidated Financial Statements

Note 19. Commitments and Contingencies (Continued)

Audubon Retirement Village

As described in Note 1, ARV executed a CEA for the operation of the Nursing Home. In conjunction with that CEA, ARV executed a lease agreement effective June 28, 2019 with LSU. The lease has an initial term of five years, with the opportunity to exercise two additional terms of five years, so that the maximum possible term of the lease is fifteen years. The annual rent is \$876,000, payable in equal quarterly installments. The annual rent will increase 2.5% each year on the anniversary of the Commencement Date, with the Commencement Date being November 1, 2019. ARV is further obligated to commence construction of improvements to the Nursing Home no later than twelve months after the Commencement Date, with costs of construction, incurred by ARV, expected to be no more than approximately \$12,500,000.

Professional and General Liability Insurance

Professional and general liability claims have been asserted against the System and are in various stages of developing. Events occurring through December 31, 2018 may result in the filing of additional claims. The System has a risk management program that provides professional and general liability coverage. Within the program, the System carries an umbrella policy for professional and general liability insurance coverage of \$25,000,000 on a claims-made basis, with a self-insured retention of \$1,000,000 per claim and \$4,500,000 in the aggregate.

Professional liability claims are limited through the System's participation in the Louisiana Patient's Compensation Fund (the Fund). The Fund was established through state legislation and statutorily limits each medical professional liability claim to \$500,000. The System is self-insured for the first \$100,000 of each claim. The remaining \$400,000 of each claim is covered by the Fund.

The System has reflected its estimate of the ultimate liability for known and incurred but not reported claims in the accompanying consolidated financial statements. The estimated liability for professional liability claims, which was discounted at 2% and 6% at December 31, 2019 and 2018, respectively, was approximately \$22,660,000 and \$21,621,000. Undiscounted professional liability claims totaled approximately \$25,587,000 and \$27,234,000 at December 31, 2019 and 2018, respectively.

Notes to Consolidated Financial Statements

Note 19. Commitments and Contingencies (Continued)

Estimated Employee Health and Workers' Compensation Claims

LCMC and its subsidiaries are covered under one health plan. The medical plan is selfinsured up to \$750,000 for non-domestic claims and fully self-insured for domestic claims. LCMC, Children's, Touro, West Jefferson, and UMCMC are self-insured for workers' compensation claims up to \$800,000. NOPS is fully insured for workers' compensation claims.

The System has a risk management program that provides excess coverage for non-domestic employee health claims and both domestic and non-domestic workers' compensation claims on an occurrence basis. The estimated liability for workers' compensation claims, discounted at 2% and 6% at December 31, 2019 and 2018, respectively, was approximately \$8,549,000 and \$7,738,000. Undiscounted workers' compensation claims totaled approximately \$9,763,000 and \$9,488,000 at December 31, 2019 and 2018, respectively. The estimated liability for employee health claims was approximately \$6,300,000 and \$6,871,000 at December 31, 2019 and 2018, respectively. Due to the short-term nature of these employee health claims liabilities, the fair value approximates the carrying value.

Note 20. Community Support

In furtherance of its charitable purpose, the System provides a broad range of community programs that are designed to meet the health needs of the community and are funded and resourced by the System. The System's Governing Board and hospital management teams work closely with local civic leaders and other healthcare providers to address the health care needs of the community.

Such community support programs include health seminars on a variety of health topics that are relevant to the health needs of the community including healthy eating, diabetes management, healthy aging, cancer support and survivorship, sexual abuse awareness, and smoking cessation. Other programs include benefits to the community such as health screenings, in-home caregiver services, counseling for patients and families, pastoral care, health enhancement and wellness programs, telephone information services, and the donation of space for use by community groups. The System also has a robust trauma prevention program including but not limited to, tourniquet training, Sudden Impact (targeting high school students), safety belt programs, and baby carrier programs.

The System provides benefits to Medicaid patients in the form of uncompensated patient care costs. The System also emphasizes the importance of higher education and funds the teaching of students and health professionals through a comprehensive graduate medical education program.

Notes to Consolidated Financial Statements

Note 20. Community Support (Continued)

Certain community support programs' revenues and expenses are excluded from operations and are shown, net, as community support on the consolidated statements of operations. This classification is driven by the magnitude of the programs and the knowledge that these programs are solely for the benefit of the community, not self-supporting or financially viable, and not a part of the System's operations. These programs, which are primarily pediatric centered, include the following: Children's Healthcare Assistance Plan (CHAP), Kids First physician practices, Children At Risk Evaluation (CARE) Center, Children's Research Institute, Limited Intervention Program, the Parenting Center, Ventilator Assisted Care Program, Safe Kids Coalition, Greater New Orleans Immunization Network, Ambulatory Clinical and Nutritional Support Services, the Miracle League, Cochlear Implant Program, and Autism Center. CHAP, one of the largest of these programs, is designed to assist families with income too high to qualify for Medicaid, but whose lack of resources limit their access to quality health care. In addition to CHAP, CHMPC increases the accessibility of health care to the indigent and underinsured through its Kids First pediatric primary care physician practices.

						2019							
	Rese	arch			(CARE	Beh	avioral		LSU			
	Inst	itute	(CHAP	C	enter	H	ealth	Re	search	LHCS	Other	Total
Patient Revenues	\$	-	\$	12,951	\$	1,561	\$	831	\$	-	\$ 7,722	\$ 7,455	\$ 30,520
Revenue Deductions		-		(12,951)		(1,229)		(744)		-	(6,171)	(5,361)	(26,456)
Other Revenues		239		-		330		-		-	526	1,366	2,461
Total Revenues		239		-		662		87		-	2,077	3,460	6,525
Total Expenses	1	I,478		3,168		2,050		990		5,774	4,321	11,515	29,296
Community Support, Net	\$ (1	l,239)	\$	(3,168)	\$	(1,388)	\$	(903)	\$	(5,774)	\$ (2,244)	\$ (8,055)	\$ (22,771)

The revenues and expenses associated with these programs for the year ended December 31, 2019, are detailed as follows (in thousands):

Notes to Consolidated Financial Statements

Note 20. Community Support (Continued)

The revenues and expenses associated with these programs for the year ended December 31, 2018, are detailed as follows (in thousands):

				20	18					
	Re	search		(CARE	Ве	havioral			
	In	stitute	CHAP	C	Center	ŀ	lealth	LHCS	Other	Total
Patient Revenues	\$	-	\$ 6,584	\$	2,152	\$	1,824	\$ 237	\$ 8,297	\$ 19,094
Revenue Deductions		-	(6,584)		(1,695)		(1,634)	-	(6,489)	(16,402)
Other Revenues	_	249	-		329		-	271	1,159	2,008
Total Revenues		249	-		786		190	508	2,967	4,700
Total Expenses		1,430	1,779		2,083		929	1,957	9,071	17,249
Community Support, Net	\$	(1,181)	\$ (1,779)	\$	(1,297)	\$	(739)	\$ (1,449)	\$ (6,104)	\$ (12,549)

The expenses presented in the tables above, include direct expenses and an allocation of indirect expenses as follows (in thousands):

	2019	2018
Direct Expenses	\$ 23,780	\$ 12,785
Indirect Expenses	5,516	4,464
Total Expenses	\$ 29,296	\$ 17,249

Indirect expenses represent estimates of patient care cost and allocated overhead using Medicare cost reporting methodologies.

Note 21. Pledges Receivable

Pledges receivable were discounted at the rate of 3.5%. At December 31, 2019, amounts included in pledges receivable were as follows (in thousands):

Pledges Receivable	\$ 3,134
Less: Discount of Long-Term Pledges	 (285)
Total	\$ 2,849

Notes to Consolidated Financial Statements

Note 21. Pledges Receivable (Continued)

Amounts due in the years ended December 31,

2020	\$		764
2021		1,	108
2022			742
2023			520
2024			-
Thereafter			-
Total	\$	3,	134

Note 22. Liquidity and Availability

Financial assets available for general expenditure, that is, without donor, or other, restrictions limiting their use, within one year of the balance sheet date, comprise the following (in thousands):

Cash and Cash Equivalents	\$ 122,753
Patient Receivables, Net	193,443
Supplemental Payments Receivable	129,121
Other Receivables	54,180
Total	\$ 499,497

Donor restricted endowment funds are not available for general expenditure.

The board designated assets that are limited as to their use for capital projects and specific programs in the amount of \$1,016,507,000 could be made available for general expenditure if necessary.

Note 23. Subsequent Events

Management evaluated subsequent events through the date the consolidated financial statements were available to be issued, May 13, 2020, and determined that the following event occurred that requires disclosure.

Subsequent to the balance sheet date of December 31, 2019, the COVID19 pandemic rapidly escalated in the State of Louisiana, and particularly New Orleans and the surrounding areas, at the beginning of March 2020, significantly impacting operations. As of the date of this report, the full impact on operations and related financial results is unknown.

Notes to Consolidated Financial Statements

Note 23. Subsequent Events (Continued)

In response to this pandemic, the United Stated Congress passed the Coronavirus Aid, Relief, and Economic Security (CARES) Act into law on March 27, 2020 in an effort to provide relief to the American people and businesses resulting from the public health and economic impacts of COVID19.

Several initial provisions of the CARES Act were specifically related to the healthcare industry. The CARES Act provided for an initial \$100 billion of funding for the healthcare industry in the form of stimulus money, treated as grants, to be released in tranches. In addition, the CARES Act provided for accelerated payments to hospitals and healthcare systems under the Medicare Accelerated Advanced Payment Program. The payments under the Medicare Accelerated Advance Payment Program will be recouped over time from hospitals and healthcare systems and, ultimately, are treated as loans.

Immediately following the enactment of the CARES Act, the government began releasing funds both in the form of stimulus monies and Medicare Advanced Payments. To date, the System has received approximately \$130 million in stimulus monies and approximately \$110 million in Medicare Advanced Payments.

Also in response to the COVID19 pandemic, the State of Louisiana, through the Louisiana Department of Health advanced certain monies to the System related to prior year open costs reports of approximately \$51 million, all of which are subject to final audit.

The remaining cash flow impact and impact on operations from the COVID19 pandemic and any Federal or State funding sources remains unknown at this time.

Effective February 27, 2020 the System signed an Asset Purchase Agreement with East Jefferson General Hospital to acquire the assets of East Jefferson General Hospital for a purchase price totaling \$105 million. The purchase price includes a \$90 million payment at time of closing and \$15 million in additional performance payments to be paid over a three-year period (\$5 million per year), contingent upon certain performance metrics.

The original closing date of the transaction was targeted for June 30, 2020. Because East Jefferson General Hospital is a government facility, the transaction requires voter approval through a public referendum which was originally scheduled for May 9, 2020.

Pursuant to the COVID19 pandemic which escalated immediately following the date of the signed Asset Purchase Agreement, both the government elections in the State of Louisiana and the originally scheduled date of the public referendum of May 9, 2020 were postponed; thereby delaying the planned closing date of the transaction. Because of the uncertainty regarding the COVID19 pandemic and the timing of elections and voter approval, it is anticipated that the closing date of the transaction will now occur during the last guarter of 2020.

No other subsequent events occurring after May 13, 2020 have been evaluated for inclusion in these consolidated financial statements.

SUPPLEMENTARY INFORMATION

LOUISIANA CHILDREN'S MEDICAL CENTER Consolidating Balance Sheet December 31, 2019 (in Thousands)

	LCMC	Touro	Children's	UMCMC	West Jefferson	LHAC	LHCS	ARV	Eliminations	Consolidated
Assets										
Current Assets										
Cash and Cash Equivalents	\$ 6,816	5 10,296 \$	5,340 \$	86,920	\$ 10,973 \$	1,517 \$	84 \$	774 \$	33 \$	122,753
Assets Limited as to Use	-	977	-	-	-	-	-	-	-	977
Patient Accounts Receivable, Net of Allowance	1	37,991	34,125	87,032	34,186	1,439	238	-	(1,569)	193,443
Pledges Receivable, Net of Discount	-	-	714	-	-	-	-	-	-	714
Other Receivables	2,180	20,092	17,887	5,382	4,264	2,623	343	1,030	379	54,180
Supplemental Payments Receivable	-	26,648	69,349	17,100	16,024	-	-	-	-	129,121
Inventories	-	6,046	5,147	10,983	6,050	-	-	-	-	28,226
Estimated Third-Party Payor Settlements	-	-	8,391	-	-	-	-	-	-	8,391
Prepaid Expenses	9,383	1,192	3,305	35,147	9,619	646	105	22	-	59,419
Total Current Assets	18,380	103,242	144,258	242,564	81,116	6,225	770	1,826	(1,157)	597,224
Assets Limited as to Use										
Investments Designated for Capital Projects										
and Specific Programs	-	68,008	948,499	-	-	-	-	-	-	1,016,507
Cash Restricted by Bond Indenture, Debt Service Reserve	-	3,284	33	-	-	-	-	-	-	3,317
Donor-Restricted Long-Term Investments	-	10,409	1,937	-	-	-	-	-	-	12,346
Restricted Other	97	39	-	-	-	-	-	-	-	136
Less: Amount Required for Current Obligations		(977)	-	-	-	-	-	-	-	(977)
Assets Limited as to Use, Net	97	80,763	950,469			-	-	-		1,031,329
Pledges Receivable, Net	-	-	2,135			-	-	-		2,135
Investments in Joint Ventures	-	56,108			1,078	-	-	-		57,186
Long-Term Portion Prepaid Leases	-	-	-	225,733	176,667	-	-	-	-	402,400
Property, Plant, and Equipment, Net	121,332	131,683	315,381	34,724	43,391	-	1,084	59		647,654
Due from Related Party	219,628	23,000	274,311	-		(2,830)	(1,522)	-	(512,587)	-
Other Assets	29,333	6,473	33,083	255	4,806	250	1,066	12,401	-	87,667
Investments in Subsidiaries	1,648,971	-	-	-	-	-	-	-	(1,648,971)	-
Total Assets	\$ 2,037,741	6 401,269 \$	1,719,637 \$	503,276	\$ 307,058 \$	3,645 \$	1,398 \$	14,286 \$	(2,162,715) \$	2,825,595

LOUISIANA CHILDREN'S MEDICAL CENTER Consolidating Balance Sheet (Continued) December 31, 2019 (in Thousands)

	LCMC	Touro	Children's	имсмс	West Jefferson	LHAC	LHCS	ARV	Eliminations	Consolidated
Liabilities and Net Assets										
Current Liabilities										
Trade Accounts Payable	\$ 34,593 \$	21,078 \$	38,366 \$	77,721	\$ 18,438 \$	135 \$	197 \$	451 \$	(1,536) \$	189,443
Accrued Salaries and Benefits	6,409	9,429	12,869	11,957	8,110	2,951	66	243	-	52,034
Current Maturities of Bonds Payable, Net of										
Deferred Financing Costs	-	3,350	-	-			-	-	-	3,350
Current Portion of Estimated Employee Health and										
Workers' Compensation Claims	535	1,415	806	1,982	2,268	69	27	-	-	7,102
Current Portion of Estimated Professional Liabilities Claims	1	1,587	313	743	862	20	2	-	-	3,528
Estimated Third-Party Payor Settlements	-	5,630	-	65,103	6,253		-	-	-	76,986
Due to Related Parties	-	6,890	-	205,789	-			-	(212,679)	-
Line of Credit	-	-	-	100,000				-	-	100,000
Other Current Liabilities	2,093	2,658	3,782	8,035	3,482	-	99	520	-	20,669
Total Current Liabilities	43,631	52,037	56,136	471,330	39,413	3,175	391	1,214	(214,215)	453,112
Bonds Payable, Net of Current Portion	323,982	48,414		-	-	-	-	-	-	372,396
Note Payable	· · · · ·	-	-	252,488				-		252,488
Estimated Employee Health and Workers' Compensation Claims,									-	
Net of Current Portion	121	1,658	505	3,030	1,336	120	11	-	-	6,781
Estimated Professional Liability Claims, Net of Current Portion	18	6,509	2,331	5,300	5,473	350	33	-	-	20,014
Employee Benefits	4,522	-	5,032	-	-	-	-	-	-	9,554
Pension Liability	-	10,723	-	-				-	-	10,723
Due to Related Parties	-	-	-	-	298,529			1,000	(299,529)	-
Other Long-Term Liabilites	22,935	3,436	6,050	-	126	-	963	11,910	-	45,420
Total Liabilities	395,209	122,777	70,054	732,148	344,877	3,645	1,398	14,124	(513,744)	1,170,488
Noncontrolling Interest	-	640	-	-		-	-			640
Net Assets										
Without Donor Restrictions	1,642,452	267,854	1,647,646	(228,872)	(37,819)	-	-	162	(1,648,971)	1,642,452
With Donor Restrictions				/	/					
Purpose Restrictions	80	4,192	1,751	-				-		6,023
Perpetual in Nature		5,806	186	-	-	-	-	-	-	5,992
Total Net Assets	1,642,532	277,852	1,649,583	(228,872)	(37,819)	-	-	162	(1,648,971)	1,654,467
Total Liabilities and Net Assets	\$ 2,037,741 \$	401,269 \$	1,719,637 \$	503,276	\$ 307,058 \$	3,645 \$	1,398 \$	14,286 \$	(2,162,715) \$	2,825,595

LOUISIANA CHILDREN'S MEDICAL CENTER Consolidating Balance Sheet December 31, 2018 (in Thousands)

	LCMC	Touro	Children's	UMCMC	West Jefferson	LHAC	LHCS	Eliminations	Consolidated
Assets									
Current Assets									
Cash and Cash Equivalents	\$ 7,658 \$	9,850 \$	33,989 \$	46,708	\$ 4,898 \$	1,390 \$	343 \$	- \$	104,836
Assets Limited as to Use	-	967	-	-	-	-	-	-	967
Patient Accounts Receivable, Net of Allowance	277	45,014	36,602	83,689	44,435	1,177	223	(1,322)	210,095
Pledges Receivable, Net of Discount	-	-	1,083	-	-	-	-	-	1,083
Other Receivables	2,047	18,358	7,610	36	3,402	1,355	23	-	32,831
Supplemental Payments Receivable	-	10,646	33,248	32,086	3,460	-	-	-	79,440
Inventories	-	5,881	5,556	11,063	6,859	-	-	-	29,359
Prepaid Expenses	7,188	1,906	2,684	36,723	7,376	111	-	-	55,988
Due from Related Parties	 51,719	-	21,398	376	-	1,059	174	(74,726)	-
Total Current Assets	68,889	92,622	142,170	210,681	70,430	5,092	763	(76,048)	514,599
Assets Limited as to Use									
Investments Designated for Capital Projects									
and Specific Programs	-	58,124	856,657	-	-	-	-	-	914,781
Restricted by Bond Indenture, Debt Service Reserve	-	3,242	53,747	-	-	-	-	-	56,989
Donor-Restricted Long-Term Investments	-	8,723	2,171	-	-	-	-	-	10,894
Restricted Other	96	28	_,	-	-	-	-	-	124
Less: Amount Required for Current Obligations	 -	(967)	-	-	-	-	-	-	(967)
Assets Limited as to Use, Net	96	69,150	912,575	-	-	-	-	-	981,821
Pledges Receivable, Net	-	-	2,938	-	-	-	-	-	2,938
Investments in Joint Ventures	-	53,884		-	1,381	-	-	-	55,265
Long-Term Portion Prepaid Lease	-	-		235,783	181,111	-	-	-	416,894
Property, Plant, and Equipment, Net	110,136	138,288	212,775	27,373	35,331	-	-	-	523,903
Due from Related Party	398,244	23,000	217,272	-	-	-	-	(638,516)	-
Other Assets	5,033	2,287	34,647	250	4,034	250	-	-	46,501
Investment in Subsidiaries	 1,444,945	-	-	-	-	-	-	(1,444,945)	
Total Assets	\$ 2,027,343 \$	379,231 \$	1,522,377 \$	474,087	\$ 292,287 \$	5,342 \$	763 \$	(2,159,509) \$	2,541,921

LOUISIANA CHILDREN'S MEDICAL CENTER Consolidating Balance Sheet (Continued) December 31, 2018 (in Thousands)

	LCMC	Touro	Children's	ИМСМС	West Jefferson	LHAC	LHCS I	Eliminations	Consolidated
Liabilities and Net Assets									
Current Liabilities									
Trade Accounts Payable \$	12,164 \$	17,337 \$	36,740 \$	75,178	\$ 16,863 \$	180 \$	148 \$	(1,322) \$	157,288
Accrued Salaries and Benefits	6,088	8,163	10,031	11,491	7,935	2,123	60	-	45,891
Current Maturities of Bonds Payable, Net	-	2,840	-	-	-	-	-	-	2,840
Current Portion of Estimated Employee Health and									
Workers' Compensation Claims	898.00	2,409	1,438	2,285	2,292	130	2	-	9,454
Current Portion of Estimated Professional Liabilities Claims	1.00	1,571	412	689	539	17	1	-	3,230
Estimated Third-Party Payor Settlements, Net	-	4,162	3,950.00	65,094	7,746	-	-	-	80,952
Due To Related Parties	19,993	11,694	178	39,140	784	2,427	538	(74,754)	-
Deferred Revenue	23	-	-	-	30	-	-	-	53
Line of Credit	-	-	-	100,000	-	-	-	-	100,000
Other Current Liabilities	1,720	3,638	2,319	4,905	3,897	-	-	(27)	16,452
Total Current Liabilities	40,887	51,814	55,068	298,782	40,086	4,877	749	(76,103)	416,160
Bonds Payable, Net of Current Portion	324,790	51,692	-	-	-	-	-	-	376,482
Note Payable	-	-	-	252,368	-	-	-	-	252,368
Estimated Employee Health and Workers' Compensation								-	
Claims, Net of Current Portion	14	1,391	882	1,975	878	149	2	-	5,291
Estimated Professional Liability Claims, Net of Current Portion	80	6,382	2,262	4,789	4,616	316	12	-	18,457
Employee Benefits	2,285	-	4,396	-	-	-	-	-	6,681
Pension Liability	-	9,417	-	-	-	-	-	-	9,417
Due to Related Parties	214,098	-	-	153,261	271,102	-	-	(638,461)	-
Other Long-Term Liabilities	858	167	-		3	-	-	-	1,028
Total Liabilities	583,012	120,863	62,608	711,175	316,685	5,342	763	(714,564)	1,085,884
Noncontrolling Interest	-	577	-	-	-	-	-	-	577
Net Assets									
Without Donor Restrictions	1,444,231	248,833	1,457,598	(237,088)	(24,398)	-	-	(1,444,945)	1,444,231
With Donor Restrictions									
Purpose Restrictions	100	3,239	1,985	-	-	-	-	-	5,324
Perpetual in Nature	-	5,719	186	-	-	-	-	-	5,905
Total Net Assets	1,444,331	257,791	1,459,769	(237,088)	(24,398)	-	-	(1,444,945)	1,455,460
Total Liabilities and Net Assets \$	2,027,343 \$	379,231 \$	1,522,377 \$	474,087	\$ 292,287 \$	5,342 \$	763 \$	(2,159,509) \$	2,541,921

LOUISIANA CHILDREN'S MEDICAL CENTER Consolidating Statement of Operations For the Year Ended December 31, 2019 (in Thousands)

	LCMC	Touro	Children's	имсмс	West Jefferson	LHAC	LHCS	ARV	Eliminations	Consolidated
Unrestricted Revenues, Gains,										
and Other Support										
Net Patient Service Revenues	\$ - \$	327,808	\$ 361,979 \$	654,413	\$ 265,070 \$	21,367 \$	-	\$ 1,626	\$ (11,814) \$	1,620,449
Provision for Doubtful Accounts	 -	-	-	-	-	-	-	-	-	
Net Patient Service Revenues Less Provision										
for Doubtful Accounts	-	327,808	361,979	654,413	265,070	21,367	-	1,626	(11,814)	1,620,449
Other Operating Revenues	151,590	26,564	15,347	76,722	15,886	15,117	-	1	(160,386)	140,841
Net Assets Released from Restrictions	 -	-	-	-	-	-	-	-	-	
Total Operating Revenues	151,590	354,372	377,326	731,135	280,956	36,484	-	1,627	(172,200)	1,761,290
Operating Expenses										
Employee Compensation and Benefits	56,778	154,956	141,977	189,126	110,284	34,842	-	826	(9,146)	679,643
Purchased Services	49,892	77,450	56,574	88,484	64,280	1,145	-	218	(123,727)	214,316
Professional Fees	11,345	18,353	48,169	165,918	24,769	77	-	1	(11,707)	256,925
Supplies and Other Expenses	16,402	68,697	63,481	234,014	74,762	420	-	420	(4,529)	453,667
Depreciation and Amortization	17,317	21,758	16,112	24,302	12,819	-	-	-	(17,317)	74,991
Interest Expense (Income)	 (113)	1,160	(8,240)	21,562	6,506	-	-	-		20,875
Total Operating Expenses	 151,621	342,374	318,073	723,406	293,420	36,484	-	1,465	(166,426)	1,700,417
(Loss) Income from Operations	(31)	11,998	59,253	7,729	(12,464)			162	(5,774)	60,873
Investment Income (Loss)		10,315	147,855	-	36	-	-	-	-	158,206
Other Nonoperating (Expense) Income	-	(132)	(58)	332	-	-	-	-	-	142
Equity in Earnings of Subsidiaries	204,026	-	-	-		-	-	-	(204,026)	-
Community Support, Net	 (5,774)	(2,131)	(17,002)	(2,645)	(993)	-	-	-	5,774	(22,771)
Excess (Deficit) of Revenues over Expenses	\$ 198,221 \$	20,050	\$ 190,048 \$	5,416	\$ (13,421) \$	- \$	-	\$ 162	\$ (204,026) \$	5 196,450

LOUISIANA CHILDREN'S MEDICAL CENTER Consolidating Statement of Operations For the Year Ended December 31, 2018 (in Thousands)

	LCMC	Touro	Children's	UMCMC	West Jefferson	LHAC	Eliminations	Consolidated
Unrestricted Revenues, Gains,								
and Other Support								
Net Patient Service Revenues	\$ 	\$ 329,759	\$ 319,095 \$	628,034	\$ 264,841 \$	17,462 \$	(9,835) \$	1,549,356
Provision for Doubtful Accounts	-	10,299	8,136	37,050	2,597	1,671	-	59,753
Net Patient Service Revenues Less Provision								
for Doubtful Accounts	-	319,460	310,959	590,984	262,244	15,791	(9,835)	1,489,603
Other Operating Revenues	150,352	21,084	46,289	39,220	10,483	13,964	(162,591)	118,801
Net Assets Released from Restrictions	224	3,701	5,455	-	-	-	-	9,380
Management Fee Revenue	-	-	-	-	-	-	-	-
Donation from Affiliate	 -	-	-	45,700	-	-	(45,700)	-
Total Operating Revenues	150,576	344,245	362,703	675,904	272,727	29,755	(218,126)	1,617,784
Operating Expenses								
Employee Compensation and Benefits	54,025	157,452	122,225	178,251	110,223	28,523	(8,346)	642,353
Purchased Services	65,997	77,816	52,333	89,294	68,681	817	(137,013)	217,925
Professional Fees	7,461	20,827	44,547	123,701	24,859	50	(12,923)	208,522
Supplies and Other Expenses	12,396	62,504	52,951	243,221	70,103	365	(3,447)	438,093
Depreciation and Amortization	10,697	20,995	14,683	19,302	10,935	-	(10,697.00)	65,915
Interest	 -	1,365	(9,054)	22,143	5,256	-	-	19,710
Total Operating Expenses	 150,576	340,959	277,685	675,912	290,057	29,755	(172,426)	1,592,518
Income (Loss) from Operations	-	3,286	85,018	(8)	(17,330)	-	(45,700)	25,266
Investment (Loss) Income	-	(3,188)	(43,782)	-	561	-	-	(46,409)
Other Nonoperating (Expense) Income	-	(213)	(166)	-	5,582	-	-	5,203
Equity in Earnings of Subsidiaries	(27,933)	-	-	-	-	-	27,933	-
Community Support, Net	 -	(15,766)	(42,483)	-	-	-	45,700	(12,549)
Excess (Deficit) of Revenues over Expenses	\$ (27,933)	\$ (15,881)	\$ (1,413) \$	(8)	\$ (11,187) \$	- \$	27,933 \$	(28,489)

LOUISIANA CHILDREN'S MEDICAL CENTER Consolidating Statement of Changes in Net Assets For the Year Ended December 31, 2019 (in Thousands)

	LCMC	Touro	Children's	UMCMC	West Jefferson	LHAC	LHCS	ARV	Eliminations	Consolidated
Changes in Net Assets Without Donor Restrictions										
Excess (Deficit) of Revenues over Expenses	\$ 198,221 \$	20,050 \$	5 190,048 \$	5,416	\$ (13,421) \$	- \$	- \$	162 \$	(204,026) \$	196,450
Excess (Deficit) of Revenues over Expenses Attributable									-	
to Noncontrolling Interests	-	(90)	-	-	-	-	-	-	-	(90)
Adjustment to Additional Minimum Pension Liability	-	(939)	-	-	-	-	-	-	-	(939)
Contribution of Right of Use Designated Equipment	 -	-	-	2,800	-	-	-	-	-	2,800
Increase (Decrease) in Net Assets Without Donor Restrictions	198,221	19,021	190,048	8,216	(13,421)	-	-	162	(204,026)	198,221
Changes in Net Assets With Donor Restrictions										
Contributions and Grants	-	363	1,215	-	-	-	-	-	-	1,578
Investment Income		1,521	-	-	-	-	-	-	-	1,521
Net Assets Released from Restriction	 (20)	(844)	(1,449)	-	-	-	-	-	-	(2,313)
(Decrease) Increase in Net Assets With Donor Restrictions	 (20)	1,040	(234)	-	-		-	-		786
Increase (Decrease) in Net Assets	198,201	20,061	189,814	8,216	(13,421)	-		162	(204,026)	199,007
Net Assets, Beginning of Year	 1,444,331	257,791	1,459,769	(237,088)	(24,398)	-	-	-	(1,444,945)	1,455,460
Net Assets, End of Year	\$ 1,642,532 \$	277,853	5 1,649,583 \$	(228,872)	\$ (37,819) \$	- \$	- \$	162 \$	(1,648,971) \$	1,654,467

LOUISIANA CHILDREN'S MEDICAL CENTER Consolidating Statement of Changes in Net Assets For the Year Ended December 31, 2018 (in Thousands)

	LC	мс	Touro	Children's	ИМСМС	West Jefferson	LHAC	E	liminations C	onsolidated
Changes in Net Assets Without Donor Restrictions										
Excess (Deficit) of Revenues over Expenses	\$	(27,933) \$	(15,881) \$	(1,413) \$	(8)	\$ (11,187) \$	-	\$	27,933 \$	(28,489)
Excess of Revenues over Expenses Attributable										
to Noncontrolling Interest		-	(117)	-	-	-	-		-	(117)
Adjustment to Additional Minimum Pension Liability		-	(670)	-	-	-	-		-	(670)
Contribution of Right of Use Designated Equipment		-	-	-	1,366	-	-		-	1,366
Ownership Revisions		-	(23)	-	-	-	-		-	(23)
(Decrease) Increase in Net Assets Without Donor Restrictions		(27,933)	(16,691)	(1,413)	1,358	(11,187)	-		27,933	(27,933)
Changes in Net Assets With Donor Restrictions										
Contributions and Grants		94	463	3,009	-	-	-		-	3,566
Investment Loss		-	(417)	-	-	-	-		-	(417)
Net Assets Released from Restriction		(224)	(3,701)	(5,455)	-	-	-		-	(9,380)
Decrease in Net Assets With Donor Restrictions		(130)	(3,655)	(2,446)	-	-	-		-	(6,231)
(Decrease) Increase in Net Assets		(28,063)	(20,346)	(3,859)	1,358	(11,187)	-		27,933	(34,164)
Net Assets, Beginning of Year	1	,472,394	278,137	1,463,628	(238,446)	(13,211)	-		(1,472,878)	1,489,624
Net Assets, End of Year	\$ 1	,444,331 \$	257,791 \$	1,459,769 \$	(237,088)	\$ (24,398) \$	-	\$	(1,444,945) \$	1,455,460



LaPorte, APAC 111 Veterans Blvd. | Suite 600 Metairie, LA 70005 504.835.5522 | Fax 504.835.5535 LaPorte.com

INDEPENDENT AUDITOR'S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING AND ON COMPLIANCE AND OTHER MATTERS BASED ON AN AUDIT OF FINANCIAL STATEMENTS PERFORMED IN ACCORDANCE WITH GOVERNMENT AUDITING STANDARDS

To the Governing Board of Trustees Louisiana Children's Medical Center New Orleans, Louisiana

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the consolidated financial statements of Louisiana Children's Medical Center (LCMC) (the System), which comprise the consolidated balance sheets as of December 31, 2019 and 2018, and the related consolidated statements of operations, changes in net assets, and cash flows for the years then ended, and the related notes to the consolidated financial statements, and have issued our report thereon dated May 13, 2020.

Internal Control Over Financial Reporting

In planning and performing our audit of the consolidated financial statements, we considered the System's internal control over financial reporting (internal control) to determine the audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of System's internal control. Accordingly, we do not express an opinion on the effectiveness of the System's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's consolidated financial statements will not be prevented or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of the internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control over financial reporting that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

LOUISIANA • TEXAS

An Independently Owned Member, RSM US Alliance RSM US Alliance member firms are separate and independent businesses and legal entities that are responsible for their own acts and omissions, and each is separate and independent from RSM US LLP. RSM US LLP is the U.S. member firm of RSM International, a global network of independent audit, tax, and consulting firms. Members of RSM US Alliance have access to RSM International resources through RSM US LLP but are not member firms of RSM International.

Compliance and Other Matters

As part of obtaining reasonable assurance about whether the System's consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the determination of financial statement amounts. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide and opinion on the effectiveness of the System's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Governmental Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose. Under Louisiana Revised Statute 24:513, this report is distributed by the Louisiana Legislative Auditor as a public document.

arte.

A Professional Accounting Corporation

Metairie, LA May 13, 2020



LaPorte, APAC 111 Veterans Blvd. | Suite 600 Metairie, LA 70005 504.835.5522 | Fax 504.835.5535 LaPorte.com

INDEPENDENT AUDITOR'S REPORT ON COMPLIANCE FOR EACH MAJOR FEDERAL PROGRAM AND ON INTERNAL CONTROL OVER COMPLIANCE REQUIRED BY THE UNIFORM GUIDANCE

To the Governing Board of Trustees Louisiana Children's Medical Center New Orleans, Louisiana

Report on Compliance for Each Major Federal Program

We have audited Louisiana Children's Medical Center (LCMC) (the System) compliance with the types of compliance requirements described in the *OMB Compliance Supplement* that could have a direct and material effect on each of the System's major federal programs for the year ended December 31, 2019. The System's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

Management's Responsibility

Management is responsible for compliance with the federal statutes, regulations, and the terms and conditions of its federal awards applicable to its federal programs.

Auditor's Responsibility

Our responsibility is to express an opinion on compliance for each of the System's major federal programs based on our audit of the types of compliance requirements referred to above. We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Those standards and the Uniform Guidance require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about the System's compliance with those requirements and performing such other procedures as we considered necessary in the circumstances.

We believe that our audit provides a reasonable basis for our opinion on compliance for each major federal program. However, our audit does not provide a legal determination of the System's compliance.

Opinion on Each Major Federal Program

In our opinion, the System complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended December 31, 2019.

LOUISIANA • TEXAS

An Independently Owned Member, RSM US Alliance RSM US Alliance member firms are separate and independent businesses and legal entities that are responsible for their own acts and omissions, and each is separate and independent from RSM US LLP. RSM US LLP is the U.S. member firm of RSM International, a global network of independent audit, tax, and consulting firms. Members of RSM US Alliance have access to RSM International resources through RSM US LLP but are not member firms of RSM International.

Report on Internal Control Over Compliance

Management of the System is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered the System's internal control over compliance with the types of requirements that could have a direct and material effect on each major federal program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for each major federal program and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of the System's internal control over compliance.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A *material weakness in internal control over compliance* is a deficiency, or combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program will not be prevented or detected and corrected on a timely basis. A *significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in a deficiency, or a combination of deficiencies, in internal control over compliance corrected on a timely basis. A *significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance is a deficiency over compliance with a type of compliance of deficiencies, in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

A Professional Accounting Corporation

Metairie, LA May 13, 2020

Schedule of Expenditures of Federal Awards For the Year Ended December 31, 2019

	Federal	Pass-Through		Federal Expenditures Recognized									Passed	
Federal Grantor/Pass-Through Agency Program Title (per CFDA)	CFDA Number	Entity Identifying Number		hildren's Hospital	Touro Infirmary	ι	лосмс	West J	lefferson		Total		ugh to cipients	
U.S. Department of Justice				•									·	
Through: Louisiana Commission on Law Enforcement														
Crime Victim Assistance	16.575	2017-VA-03-4195 & 2018-VA-03- 4849	\$	230,852	\$-	\$	-	\$	-	\$	230,852	\$	-	
Crime Victim Assistance	16.575	2017-VA-03-4194 & 2018-VA-03- 4850		68,105	-		-		-		68,105		-	
Crime Victim Assistance	16.575	2016-VA-01/02/03/04-4063		-	-		59,480		-		59,480		-	
Total U.S. Department of Justice				298,957	-		59,480		-		358,437		-	
U.S. Department of Public Safety Through: Louisiana Transportation Research Center														
Destination Zero Deaths	20.000	H.012710		-	-		5,658		-		5,658		-	
Highway Safety Cluster Through: Louisiana Highway Safety Commission														
State and Community Highway Safety	20.600	2019-55-10		-	-		168,254		-		168,254		-	
State and Community Highway Safety	20.600			-	-		201,649		-		201,649		-	
Total Highway Safety Cluster				-	-		369,903		-		369,903		-	
Total U.S. Department of Transportation				-	-		375,561		-		375,561		-	
U.S. Department of Education														
Through: Louisiana Department of Education Special Education Grants to States	84.027A			165,718	-		-		-		165,718		-	
Total U.S. Department of Education				165,718	-		-		-		165,718		-	
U.S. Department of Health and Human Services Direct Award														
Grants to Provide Outpatient Early Intervention Services with Respect to HIV Disease	93.918	6 H76HA26800-06-02		-	-		795,576		-		795,576		-	
Response Activities National Bioterrorism Hospital Preparedness Program	93.889			23,868	-		-		-		23,868		-	

Schedule of Expenditures of Federal Awards (Continued) For the Year Ended December 31, 2019

	Federal	Pass-Through		Passed				
Federal Grantor/Pass-Through Grantor Program Title	CFDA Number	Entity Identifying Number	Children's Hospital	Touro Infirmary	имсмс	West Jefferson	Total	Through to Subrecipients
Through: City of New Orleans			reopital		00			<u>ous oup on to </u>
HIV Emergency Relief Project Grants	93.914	K18-916	-	-	1,221,102	-	1,221,102	-
Through: Louisiana State University Health Science Center								
Breast and Cervical Health Program	93.898	5 NU58DP006332-02-00	-	-	56,998	-	56,998	-
Research and Development Cluster								
Through: The University of Texas Health Science Center at Houston Blood Disorder Program: Prevention, Surveillance, and Research	93.080	5NU27DD001155-02-00	12.711	_	_	_	12.711	_
Maternal and Child Health Federal Consolidated Programs	93.110	2H30MC24051-06	13,144	-	-	-	13,144	-
Through: Louisiana State University Health Science Center								
Cancer Treatment Research	93.395	5UG1CA189854-04	125,229	-	-	-	125,229	-
Through: Emory University								
Hematopoietic Stem Cell Transplantation for Young Adults with Sickle Cell Disease-Clinical Coordinating Center	93.839	5U01HL128566-04 & 5U01HL128566-05	570	-	-	-	570	-
Through: The Research Institute at Nationwide Children's Hospital								
Integrative Proteomics & Metabolomics for Pediatric Glomerula Disease Biomarkers/CUREGN 2.0 - Midwest Pediatric Nephrology Consortium - PCC	93.847	5UM1DK100866-05 REVISED & 2U01DK100866-07	5,108	-	-	-	5,108	-
Through: The Board of Supervisors of Louisiana State University								
on behalf of its LSU Health Science Center								
Advanced Nurse Education-Sexual Assault Nurse Examiner Program	93.247	6T96HP32497-01-01 & T96HP32497-02-00	5,520	-	-	-	5,520	-
Through: Washington University								
Sickle Cell Treatment Demonstration Program	93.365	2U1EMC27865-04-00	42,162	-	-	-	42,162	-
Through: The Research Institute at Nationwide Children's Hospital Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847	5UM1DK100866-05	44,154				44,154	
	93.047		44,154	-	-	-	44,154	-
Through: Louisiana State University Agricultural and Mechanical College Biomedical Research and Research Training	93.859	2U54GM104940-02 & 5U54GM104940-03	58,422		-	-	58,422	-
Through: Hudson Alpha Institute for Biotechnology								
DNA Sequencing for Newborn Nurseries	93.172	5U01HG007301-06	42,449	-	-	-	42,449	-
Through: University of Kansas Medical Center Research Institute								
Feeding Protocol for Children with Chronic Medical Conditions	93.865	1r01HD93933-01A1	18,396	-	-	-	18,396	-
Total Research and Development Cluster			367,864	-	-	-	367,864	-
Total U.S. Department of Health and Human Services			391,733	-	2,073,676	-	2,465,408	-
U.S. Department of Homeland Security: Through: State of Louisiana								
Disaster Grants - Public Assistance (Presidentially Declared Disasters)	97.036		77,927	-	-	-	77,927	-
Total U.S. Department of Homeland Security			77,927	-	-	-	77,927	-
Total Expenditures of Federal Awards			\$ 934,335	\$ -	\$ 2,508,717	\$-	\$ 3,443,051	\$ -

Notes to Schedule of Expenditures of Federal Awards For the Year Ended December 31, 2019

Note 1. Basis of Presentation

The accompanying schedule of expenditures of federal awards (the Schedule) includes the federal grant activity of Children's Hospital, Touro Infirmary and its Subsidiaries (Touro Infirmary), University Medical Center Medical Corporation (UMCMC) and West Jefferson under programs of the federal government for the year ended December 31, 2019, and is presented on the full accrual basis of accounting. The information in this Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Because the Schedule presents only a selected portion of the operations of the System, it is not intended to and does not present the financial position, changes in net assets, or cash flows of the System.

Note 2. De Minimis Cost Rate

The System has not elected to use the 10-percent de minimis indirect cost rate allowed under the Uniform Guidance.

Schedule of Findings and Questioned Costs For the Year Ended December 31, 2019

Part I - Summary of Auditor's Results

Financial Statement Section

Type of Auditor's Report Issued:	Unmodified
Internal Control over Financial Reporting: Material Weakness(es) Identified? Significant Deficiency(ies) Identified not Considered to be Material Weakness? Noncompliance Material to Financial Statements Noted?	No None Reported No
Federal Awards Section	
Internal Control over Major Programs: Material weakness(es) identified? Significant Deficiency(ies) Identified not Considered to be Material Weakness?	No None Reported
Type of Auditor's Report Issued on Compliance for Major Federal Programs:	Unmodified
Any Audit Findings Disclosed that are Required to be Reported in Accordanc with 2 CFR 200.516(a)?	e No
Identification of Major Programs:	
	-DA Number
Highway Safety Cluster	20.600
Grants To Provide Outpatient Early Intervention Services With Respect To HIV Disease	93.918
Dollar Threshold used to Distinguish between Type A and Type B Programs:	\$750,000
Auditee Qualified as Low-Risk Auditee?	Yes

Schedule of Findings and Questioned Costs (Continued) For the Year Ended December 31, 2019

Part II - Schedule of Financial Statement Findings Section

None.

Part III - Federal Awards Findings and Questioned Costs Section

None.

Summary Schedule of Prior Year Findings For the Year Ended December 31, 2019

Part I - Financial Statement Findings

None.

Part II - Federal Award Findings and Questioned Costs

None.